<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006212.pub3" GROUP_ID="PVD" ID="102306051816124752" MERGED_FROM="" MODIFIED="2009-12-08 17:02:44 +0100" MODIFIED_BY="Karen Welch" REVIEW_NO="1091" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2009-12-08 17:02:44 +0100" MODIFIED_BY="Karen Welch">
<TITLE>Vena caval filters for the prevention of pulmonary embolism</TITLE>
<CONTACT MODIFIED="2009-12-08 17:02:44 +0100" MODIFIED_BY="Karen Welch"><PERSON ID="47B6F09882E26AA20145240AECEEFA2D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tim</FIRST_NAME><LAST_NAME>Young</LAST_NAME><POSITION>Thoracic, Sleep and General Physician</POSITION><EMAIL_1>timyoung1@optusnet.com.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory and Sleep Medicine</DEPARTMENT><ORGANISATION/><ADDRESS_1>PO Box M103</ADDRESS_1><ADDRESS_2>Missenden Road</ADDRESS_2><CITY>Camperdown</CITY><ZIP>2050</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 4 1144 7780</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-12-08 17:02:44 +0100" MODIFIED_BY="Karen Welch"><PERSON ID="47B6F09882E26AA20145240AECEEFA2D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tim</FIRST_NAME><LAST_NAME>Young</LAST_NAME><POSITION>Thoracic, Sleep and General Physician</POSITION><EMAIL_1>timyoung1@optusnet.com.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory and Sleep Medicine</DEPARTMENT><ORGANISATION/><ADDRESS_1>PO Box M103</ADDRESS_1><ADDRESS_2>Missenden Road</ADDRESS_2><CITY>Camperdown</CITY><ZIP>2050</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 4 1144 7780</PHONE_1></ADDRESS></PERSON><PERSON ID="47D11BE082E26AA20145240AD30767ED" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Hangwi</FIRST_NAME><LAST_NAME>Tang</LAST_NAME><POSITION>Thoracic and Sleep Physician</POSITION><EMAIL_1>hangwitang@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory and Sleep Medicine</DEPARTMENT><ORGANISATION>Princess Alexandra Hospital</ORGANISATION><ADDRESS_1>Ipswich Road</ADDRESS_1><ADDRESS_2>Woollongabba</ADDRESS_2><CITY>Brisbane</CITY><ZIP>4102</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 3240 2111</PHONE_1><FAX_1>+61 7 3240 6170</FAX_1></ADDRESS></PERSON><PERSON ID="47CA04D082E26AA20145240AC2965F03" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rodney</FIRST_NAME><LAST_NAME>Hughes</LAST_NAME><POSITION>Thoracic Physician</POSITION><EMAIL_1>rodney.hughes@sth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Sheffield Pulmonary Vascular Diseases Unit</DEPARTMENT><ORGANISATION>Royal Hallamshire Hospital</ORGANISATION><ADDRESS_1>Glossop Road</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S10 2JF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 114 271 1900</PHONE_1><PHONE_2>+44 779 003 3918</PHONE_2><FAX_1>+44 114 271 1718</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-10-22 10:45:23 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="21" MONTH="10" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="10" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="3" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2009-10-22 10:46:07 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-10-22 10:46:07 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Searches updated and one additional RCT included. Conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2009-10-22 10:45:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>John Aukes removed as author from the updated review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-01-30 14:31:51 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-30 14:30:48 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-21 16:12:17 +0100" MODIFIED_BY="Heather  Maxwell">
<DATE DAY="9" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>One additional reference (conference abstract) added to the included study (PREPIC). No change to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-04-21 12:03:15 +0100" MODIFIED_BY="Heather  Maxwell">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Citation order revised on request of review author.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-04-21 15:23:56 +0100" MODIFIED_BY="Heather  Maxwell">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2008-04-21 15:23:56 +0100" MODIFIED_BY="Heather  Maxwell">
<SOURCE MODIFIED="2008-04-21 15:23:56 +0100" MODIFIED_BY="Heather  Maxwell">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-05 10:45:35 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-10-22 11:08:01 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Vena caval filters for the prevention of pulmonary embolism</TITLE>
<SUMMARY_BODY MODIFIED="2009-10-22 11:08:01 +0100" MODIFIED_BY="[Empty name]">
<P>Blood clots in the lungs are called pulmonary emboli. They originate in the legs, fragment and travel to the lungs via the inferior vena cava. Vena caval filters are metal alloy devices inserted within the inferior vena cava to trap blood clots and thus prevent pulmonary emboli. Further emboli are usually prevented by blood thinning medications (anticoagulants).</P>
<P>In some instances (approximately 4% of cases), anticoagulation alone is insufficient to prevent more emboli or it is too dangerous for anticoagulation to be given because the person has a high risk of bleeding. Blood clots are known to occur as a result of certain types of surgery or injuries, and are more likely to fragment if they extend into the thigh or pelvis.</P>
<P>Vena caval filters have been in use since the 1970s and were designed to be left permanently within the inferior vena cava. The latest generation of filters are temporary or 'retrievable'. They can be removed at the manufacturer's recommendation between two to 12 weeks, if their use is no longer required. However, despite being called retrievable, a number of retrievable filters cannot be removed because of complications. The long-term safety profile of these devices left inside the body remains to be seen. The authors looked for articles comparing permanent and temporary (or retrievable) filters and comparisons between the different filter designs.</P>
<P>Two trials were included in the review involving a total of 529 people. No recommendations can be made regarding filter efficacy in preventing pulmonary embolism. One trial which was conducted in 1972 showed a reduction in pulmonary embolism rates but not deaths in a group of people who suffered traumatic hip fractures and who had a filter inserted. No preventive DVT treatment was given as this was controversial at the time. Outcomes were given at 34 days.The trial participants were inadequately randomised, had a higher proportion of people who were not able to undergo surgical fixation in the control group, and outcome assessors were not blinded.</P>
<P>In the PREPIC trial, caval filters were associated with an increased risk of blood clot formation in the legs following their insertion. This study did not demonstrate any difference in the death rates between the two groups; the participants were older (average age 73 years) with co-existing medical conditions and the majority of people died from cancer-related causes or heart problems. No details were recorded of adverse events of filters, but the numbers in this trial were not of sufficient size to detect them.</P>
<P>There is a lack of information on the effectiveness of caval filters in other clinical scenarios, especially in the two situations where they are used most frequently and thought to be the most advantageous. These are when patients cannot be anticoagulated, or when pulmonary embolism occurs despite adequate anticoagulation. Vena caval filter use is increasing and more trials are needed to confirm their benefit and accurately assess their safety. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-11-05 10:15:51 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-10-22 10:58:40 +0100" MODIFIED_BY="[Empty name]">
<P>Pulmonary emboli (PE) can have potentially fatal consequences. Inferior vena caval filters (VCFs) are metal alloy devices that mechanically trap fragmented thromboemboli from the deep leg veins en route to the pulmonary circulation. Filters are designed to be introduced (and in the case of retrievable filters, removed) percutaneously. Although their deployment seems of theoretical benefit, their clinical efficacy and adverse event profile is unclear.</P>
<P>This is an update of a Cochrane review first published in 2007.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-10-22 10:58:52 +0100" MODIFIED_BY="[Empty name]">
<P>To examine evidence for the effectiveness of VCFs in preventing pulmonary embolism (PE). Secondary outcomes were mortality, distal (to filter) thrombosis, and filter-related complications.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-10-22 11:06:53 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched October 2009) and the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I> 2009, Issue 4 for randomised or controlled clinical trials of VCFs for the prevention of PE. The authors contacted filter manufacturers for information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-10-22 11:06:31 +0100" MODIFIED_BY="[Empty name]">
<P>Controlled clinical trials (CCTs) and randomised controlled trials (RCTs) that examined the efficacy of filters in preventing PE.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-10-22 11:26:36 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-11-05 10:15:51 +0000" MODIFIED_BY="[Empty name]">
<P>Two studies were included involving a total of 529 people. One open quasi-randomised trial of 129 participants with traumatic hip fractures showed a reduction in PE but not mortality over a 34 day period in the filter group. The PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) trial, was an open RCT of 400 participants with documented proximal deep vein thrombosis (DVT) or PE who received concurrent anticoagulation. Permanent VCFs prevented PE at eight years. No reduction in mortality was seen, but this reflected an older study population; the majority of deaths were due to cancer or cardiovascular causes. There was an increased incidence of (DVT) in the filter group. Adverse events were not reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-10-22 11:05:19 +0100" MODIFIED_BY="[Empty name]">
<P>No recommendations can be drawn from the two studies. One study showed a reduction in PE rates but not mortality, but was subject to significant biases. The PREPIC study lacked statistical power to detect a reduction in PE over shorter and more clinically significant time periods. However, the trial demonstrated that permanent VCFs were associated with an increased risk of long term lower limb DVT.</P>
<P>There is a paucity of VCFs outcome evidence when used within currently approved indications and a lack of trials on retrievable filters. Further trials are needed to assess vena caval filter safety and effectiveness. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-11-05 10:45:35 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-10-22 11:11:52 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-02-04 10:26:00 +0000" MODIFIED_BY="[Empty name]">
<P>Blood clots or deep venous thrombosis (DVT) form in the lower extremities and can occur under a number of different circumstances. Temporary circumstances are prolonged immobility, recent surgery, trauma, pregnancy, or oestrogen therapy. Longer term situations include people who have cancer, or people who have an inherited hypercoagulable tendency.</P>
<P>Deep vein thromboses can fragment and travel through the venous system to the lungs causing pulmonary embolism (PE). The major conduit of venous drainage from the lower half of the body is the inferior vena cava.</P>
<P>Deep vein thromboses that extend into the thigh or pelvis are more likely to embolise than those that do not extend beyond the calf. Case series data indicate a rate between 27% to 60% for the risk of embolism if the clot is situated either within the inferior vena cava or the thigh or pelvic veins (<LINK REF="REF-Norris-1985" TYPE="REFERENCE">Norris 1985</LINK>; <LINK REF="REF-Radomski-1987" TYPE="REFERENCE">Radomski 1987</LINK>).</P>
<P>The current treatment for pulmonary embolism is anticoagulation (heparin and vitamin K antagonists (warfarin, coumadin)). Infrequently, recurrent pulmonary emboli can occur despite therapeutic levels of anticoagulation; Douketis suggested a rate of 3.8% in a systematic review of the literature (<LINK REF="REF-Douketis-1998" TYPE="REFERENCE">Douketis 1998</LINK>).</P>
<P>Deep vein thromboses can also occur in the upper limbs and neck, because of the increasing use of semi-permanent venous access devices and catheters. They can embolise to the lungs via the superior vena cava.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-02-04 10:26:21 +0000" MODIFIED_BY="[Empty name]">
<P>The concept of caval interruption was identified as far back as the 1700s. The first surgical vena caval ligation (complete occlusion of the vena cava with sutures or external clips) was successfully performed in 1893. It required general anaesthesia and abdominal surgery, and was associated with considerable mortality. Vena caval ligation in the 1960s carried an operative mortality risk of 14%, and pulmonary embolism still occurred at a rate of 6% (due to the development of a large collateral circulation) with fatal embolism occurring at a rate of 2% (<LINK REF="REF-Greenfield-1992" TYPE="REFERENCE">Greenfield 1992</LINK>). Anticoagulation became the mainstay of treatment in the 1950s. Filters which could be inserted percutaneously were developed in the 1970s, and are used in increasing numbers.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-02-04 10:27:35 +0000" MODIFIED_BY="[Empty name]">
<P>Vena caval filters may be placed in the inferior or superior vena cava to mechanically trap emboli, interrupting their course before reaching the heart and lungs. These devices most commonly resemble an umbrella in appearance, are made from metal alloys, and can be inserted percutaneously. Inferior vena caval filters are usually inserted below the level of the renal veins.</P>
<P>Once deployed, permanent filters are left in situ; they become endothelialised and are eventually incorporated within the blood vessel wall. Temporary or retrievable (also known as optional) filters are recent developments in which filters can be removed within a certain time interval (specified by the manufacturer) if their use is no longer required. This time period may extend to approximately 12 weeks, depending on the clinical experience of the interventional radiologist. There are currently approximately 12 filter designs, several of which are retrievable. Retrievable filters have potential advantages over the permanent filters; one is the opportunity for subsequent removal if no longer needed, thus avoiding longer term sequelae of DVT. They can also be repositioned within the vena cava if significant incorporation into the endothelium/endothelialisation has not occurred. Despite being called 'retrievable', these filters can become permanent implants if their subsequent removal becomes complicated due to endothelialisation, or if there is a significant amount of trapped thrombus within the filter such that the filter cannot be retracted back into its sheath, thus preventing percutaneous removal.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-10-22 11:11:52 +0100" MODIFIED_BY="[Empty name]">
<P>Pulmonary embolism is a major cause of hospital morbidity and mortality.</P>
<P>The majority of retrievable filters have been designed for temporary use only. Whilst reports suggest that they can be left in situ longer term (<LINK REF="REF-Kirilcuk-2005" TYPE="REFERENCE">Kirilcuk 2005</LINK>), the safety of this practice has not been extensively evaluated.</P>
<P>Filters are strongly recommended for two groups of people: those who have a proximal DVT or pulmonary embolism, or both, where it is too dangerous for them to receive anticoagulation; and those who continue to have recurrent emboli despite already receiving appropriate levels of anticoagulation (<LINK REF="REF-Buller-2004" TYPE="REFERENCE">Buller 2004</LINK>).</P>
<P>There is controversy in the literature about whether other groups of people may potentially benefit from having a vena caval filter inserted (<LINK REF="REF-Hann-2005" TYPE="REFERENCE">Hann 2005</LINK>; <LINK REF="REF-Kinney-2003" TYPE="REFERENCE">Kinney 2003</LINK>). These include:</P>
<UL>
<LI>people with extensive trauma without established venous thromboembolism;</LI>
<LI>people with large free-floating ilio-femoral thrombosis who do or do not subsequently receive thrombolytic therapy for this;</LI>
<LI>people with cancer and concurrent venous thromboembolism;</LI>
<LI>pregnant women who have venous thromboembolism.</LI>
</UL>
<P>The studies and the interventions examined in this review were to assess the efficacy and safety of filters; whether efficacy and safety varied amongst the different filter designs, and with different concurrent antithrombotic drugs.<BR/>
</P>
<P>We intended the comparisons in this review to be as follows.</P>
<OL>
<LI>Filters versus no filter in those people for whom anticoagulation is contraindicated.</LI>
<LI>Filters and anticoagulants versus anticoagulants alone.</LI>
<LI>Filters with anticoagulation versus filters with no anticoagulation, seeking to answer the question as to whether long-term anticoagulation is recommended with permanent filters in situ; there is considerable debate about this (<LINK REF="REF-Gomes-2003" TYPE="REFERENCE">Gomes 2003</LINK>).</LI>
<LI>Trials of filters with newer antithrombotic drugs, of interest as these newer agents may have greater antithrombotic action or less haemorrhagic complications. Both of these effects are relevant to current indications for filters and fondaparinux appears to have fewer haemorrhagic complications (<LINK REF="REF-Yusuf-2006" TYPE="REFERENCE">Yusuf 2006</LINK>).</LI>
<LI>Permanent versus temporary filters to look at which type of filter is most effective, but also to investigate respective rates of complications.</LI>
<LI>Direct comparison of filter brands, to see if any one filter is superior in terms of its filtering efficiency or low rate of complications.</LI>
</OL>
<P>Comparisons of filters versus no filters also examine the complications and adverse effects from having filters in situ. Pooled case series data indicate a recurrent PE rate of 2% to 5% with a fatal PE rate of 0.7%, despite the presence of a filter. The mortality rate from complications related to filter insertion is 0.12%. Filter migration has been estimated to occur at rates up to 69% and inferior vena caval perforation up to 24%, though these figures reflect radiological findings and not necessarily clinical events. Deep vein thrombosis was reported to occur at rates up to 45.7%, and post-thrombotic syndrome up to 59% (<LINK REF="REF-Kinney-2003" TYPE="REFERENCE">Kinney 2003</LINK>); these problems occurred more frequently with longer durations of follow up. It is controversial as to whether these lower limb complications are the result of having a filter in situ, or are part of the intrinsic pro-thrombotic tendency these people may have.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the evidence for vena caval filters in preventing pulmonary embolism.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-05 10:33:42 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-10-22 11:21:38 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled trials and controlled clinical trials that studied the effectiveness of vena caval filters in preventing pulmonary embolism.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-01-30 15:19:22 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were considered for inclusion in trials if they were aged 18 or older and:</P>
<UL>
<LI>had radiologically confirmed proximal deep venous thrombosis or pulmonary embolism, or both;</LI>
</UL>
<P>or</P>
<UL>
<LI>were considered to be at high risk of deep venous thrombosis or pulmonary embolism, with contraindications to anticoagulation.</LI>
</UL>
<P>Trials were excluded from the review if the participants had a life expectancy of less than four weeks when given treatment or if they had previous permanent vena caval filter placement.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-02-04 11:20:00 +0000" MODIFIED_BY="[Empty name]">
<P>We searched for studies in which participants aged 18 or older with radiologically confirmed proximal deep venous thrombosis or pulmonary embolism, or both, received:</P>
<UL>
<LI>vena caval filter versus no filter in people for whom anticoagulation was contraindicated;</LI>
<LI>vena caval filter and anticoagulation (heparin, low molecular weight heparin (LMWH), and vitamin K antagonists) versus anticoagulation (and no filter);</LI>
<LI>permanent vena caval filter versus temporary vena caval filter;</LI>
<LI>direct comparisons between filter brands;</LI>
<LI>vena caval filter with newer antithrombotic drugs (fondaparinux, hirudin) versus newer antithrombotic drugs (without filter).</LI>
</UL>
<P>Participants aged 18 or older at high risk of deep venous thrombosis and pulmonary embolism and in whom anticoagulation was contraindicated receiving:</P>
<UL>
<LI>vena caval filter with mechanical prophylaxis versus no filter and mechanical prophylaxis (includes graded compression stockings, intermittent pneumatic compression, venous foot pump).</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-10-22 11:21:38 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-10-22 11:21:18 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Pulmonary embolus as demonstrated by computer tomography (CT), pulmonary angiography or ventilation-perfusion lung scan.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-10-22 11:21:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mortality.</LI>
<LI>Filter-related complications - mortality, embolisation, clinical perforation.</LI>
<LI>Distal (to filter) thrombosis - vena caval thrombosis and limb deep venous thrombosis as documented by ultrasonography impedence.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-11-05 10:31:53 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-11-05 10:31:53 +0000" MODIFIED_BY="[Empty name]">
<P>The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched October 2009) and the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I> (last searched 2009, Issue 4), see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the Trials Search Co-ordinator and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library.</I>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-02-04 10:11:27 +0000" MODIFIED_BY="[Empty name]">
<P>Citations within identified studies were analysed. In addition, specialists known to be involved with trials of vena caval filters, individual authors, and biomedical companies manufacturing vena caval filters were contacted for details of unpublished or ongoing trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-05 10:33:42 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-02-04 11:22:20 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled and controlled clinical trials of vena caval filters looking at their efficacy in preventing pulmonary embolism were included.</P>
<P>We collected the following information:<BR/>
</P>
<UL>
<LI>incidence of radiologically confirmed pulmonary embolism;</LI>
<LI>mortality;</LI>
<LI>rates of distal (to filter) venous thrombosis;</LI>
<LI>filter-related complications.</LI>
</UL>
<P>Subgroups of interest that were analysed consisted of:</P>
<UL>
<LI>people who had a contraindication to anticoagulation;</LI>
<LI>people who had another episode of pulmonary embolism despite being anticoagulated;</LI>
<LI>people who had cancer and co-existing venous thromboembolism;</LI>
<LI>pregnant women who had venous thromboembolism;</LI>
<LI>people who had superior vena caval filters inserted for upper limb venous thrombosis;</LI>
<LI>people who had supra-renal vena caval filters inserted;</LI>
<LI>people who had filters inserted versus those receiving the newer antithrombotic drugs;</LI>
<LI>comparisons between permanent and temporary filters;</LI>
<LI>comparisons between filter brands.</LI>
</UL>
<P>Three authors (TY, HT and RH) independently identified all studies which satisfied the inclusion criteria; TY obtained the full text of the identified studies; TY, HT and RH independently assessed trials for inclusion in the review. If there was disagreement, RH was consulted. Trial authors were contacted for further information in the context of missing or incomplete data.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-02-04 11:22:40 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (TY and HT) independently extracted data according to the PVD Group's data extraction sheet. Incidence figures of desired outcomes were transcribed from the data tables provided.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-11-05 10:33:42 +0000" MODIFIED_BY="[Empty name]">
<P>We used the criteria for assessing risk of bias as provided in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). The following domains were assessed as 'Yes' (low risk of bias), 'Unclear' (uncertain risk of bias) or 'No' (high risk of bias):</P>
<UL>
<LI>randomisation;</LI>
<LI>concealment of allocation;</LI>
<LI>blinding (of participants, personnel and outcome assessors);</LI>
<LI>incomplete outcome data;</LI>
<LI>selective outcome reporting;</LI>
</UL>
<P>For the original review each trial was evaluated for quality according to the Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). This is a 5-point score which is based on the adequacy of randomisation, blinding and follow up. A maximum of two points was awarded if the word randomised or randomisation was stated and the sequence of number generation was described and was truly unpredictable. A maximum of two points was also allocated if the intervention was double blinded, no points were given for open trials; and one point was scored for adequate description of participant withdrawals and drop-outs during the study.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-02-04 11:24:03 +0000" MODIFIED_BY="[Empty name]">
<P>Dichotomous data were assessed by relative risk estimates and hazard ratios.</P>
</EFFECT_MEASURES>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-11-03 16:09:52 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-11-03 16:09:52 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2009-11-03 16:09:52 +0000" MODIFIED_BY="[Empty name]">
<P>See the flow diagram of the search results, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>The search for trials found two randomised controlled trials, one of which had an eight-year follow up, and nine clinical trials for assessment. Three controlled clinical trials had major methodological flaws as the interventional and control groups were not comparable or details were not stated; three others used a prospective cohort against an historical control. Two clinical trials were, in fact, case series. One was a cost-effectiveness analysis.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-10-22 12:03:03 +0100" MODIFIED_BY="[Empty name]">
<P>Summary details of included studies are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>
<LINK REF="STD-Fullen-1973" TYPE="STUDY">Fullen 1973</LINK> was a quasi-randomised open trial with 129 participants in a single centre in the US. All participants who had a traumatic hip fracture were asked to be involved in the study. The mean ages in the filter group and control group were 69 and 67 years respectively. The gender distribution was not documented. There seemed to be a greater proportion of people with atherosclerotic heart disease and cardiac failure allocated to the filter group. Exclusion criteria was refusal to consent to participating in the trial.</P>
<P>People included in the trial were randomised to receive a (Mobin-Uddin) caval filter. Primary outcomes were pulmonary embolism on a definite, probable or possible occurrence (based on clinical, imaging and post-mortem data), and mortality. Secondary outcomes were complications from surgery or the filter. Dates of outcome assessments were not stated; investigations for pulmonary embolic disease were performed when clinically suspected. The average length of stay was 33 and 34 days between the two groups; no range values were listed.</P>
<P>There was a reduction in pulmonary embolism in the filter group; with the only case in the filter group occurring prior to filter insertion.</P>
<P>Seven people could not have internal fixation, one in the filter group and six in the control group.</P>
<P>Filters could not be inserted into seven people randomised to the filter group. A jugular approach was used. Filters could not be placed into these seven people due to narrow central veins or difficulty negotiating the filter through the right atrium in severe kyphosis. No anticoagulation was used by any participant. Small doses of aspirin may have been taken by a number of control participants (no figure given but described as "occasional'').</P>
<P>The <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK>
<B> </B>study was a randomised controlled open trial with 400 participants from multiple (44) centres in France. Participants consisted of consecutive hospitalised people, made up of 64% males with an average age of 73 years, with documented proximal DVT or pulmonary embolism and considered by the referring physician to be at high risk of pulmonary embolism. There were numerous exclusion criteria; notably people were excluded if they failed or had contraindications to anticoagulation, or if they were pregnant. <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> had a 2 x 2 factorial design with interventions of (permanent) caval filter versus no filter, and low molecular weight heparin (LMWH) versus unfractionated heparin. Primary outcomes were: pulmonary embolism, mortality, and deep venous thrombosis. Secondary outcomes were: bleeding, post-thrombotic syndrome, and filter-related complications. Outcomes were assessed at 12 days, two years, and eight years.</P>
<P>Analysis of the rates of pulmonary embolism showed that they were not statistically different between the LMWH and unfractionated heparin groups, so they were considered to be equivalent treatments.</P>
<P>Both study groups received vitamin K antagonists for the first three months; at eight years, 35% of people in both study groups were still receiving vitamin K antagonists. Similar proportions of people In both groups wore elastic stockings (45% and 47% in the filter and no-filter group respectively) at eight years.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-08-28 09:58:43 +0100" MODIFIED_BY="[Empty name]">
<P>Details of excluded studies are given in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. Three studies (<LINK REF="STD-Khansarinia-1995" TYPE="STUDY">Khansarinia 1995</LINK>, <LINK REF="STD-Rodriguez-1996" TYPE="STUDY">Rodriguez 1996</LINK>, and <LINK REF="STD-Rosner-2004" TYPE="STUDY">Rosner 2004</LINK>) were excluded as they were designed to compare prospective interventional cohorts with historical controls. <LINK REF="STD-Brasel-1997" TYPE="STUDY">Brasel 1997</LINK> was excluded as it was a cost-effectiveness study. <LINK REF="STD-Midy-1994" TYPE="STUDY">Midy 1994</LINK> and <LINK REF="STD-Rosenthal-1994" TYPE="STUDY">Rosenthal 1994</LINK> were case series. <LINK REF="STD-Gosin-1997" TYPE="STUDY">Gosin 1997</LINK> and <LINK REF="STD-Rogers-1997" TYPE="STUDY">Rogers 1997</LINK> did not have comparable prospective interventional and control groups; only selected high-risk people received filters, and prospective interventional cohorts were compared with historical controls. In <LINK REF="STD-Webb-1992" TYPE="STUDY">Webb 1992</LINK>, only selected high-risk people received filters, and there were no data regarding baseline characteristics of the intervention and control groups. These people also received concurrent prophylactic anticoagulation in the setting of trauma (acetabular fracture).</P>
<P>Several large case series were considered but could not be included within this review due to their methodology (primarily related to their lack of an adequate control group).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-10-22 12:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>
<LINK REF="STD-Fullen-1973" TYPE="STUDY">Fullen 1973</LINK> was randomised on the basis of hospital numbers (odd or even). The study was an open design. Participation in the filter group required consent and the insertion procedure. Baseline characteristics were scarce. A higher rate of atherosclerotic heart disease and cardiac failure was noted in the filter group. Co-interventions (usage of anticoagulation) was similar between the groups, as was time from admission-to-filter insertion and admission-to-fracture fixation. Seven people could not undergo fracture fixation - six of these were in the control group. It is not stated whether the outcome assessors were blinded or not. Diagnostic imaging for PE was not stated as being a routine part of the trial. The use of plain chest radiography for the diagnosis of PE is inaccurate. Follow up was complete as this was an in-hospital population. Analysis was not by intention to treat. Inclusion and exclusion criteria were briefly stated. Primary outcomes of mortality and PE were given, as were details related to filter complications. No DVT rates were reported. </P>
<P>The <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study was randomised by a centralised computer telephone system. The study was an open design. An independent adjudication committee who assessed all radiological and clinical outcomes was blinded to the treatment status of the participants. Baseline characteristics and co-interventions (including the proportion of people receiving vitamin K antagonists and wearing elastic stockings) were similar between the intervention and control groups. Withdrawals and drop outs were few and appropriately described in the manuscript. Participant cross over was 10% (19 people initially assigned to the no-filter group subsequently received a filter). An intention-to-treat analysis was performed. Inclusion and exclusion criteria were clearly stated. Primary and secondary outcomes were reported. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-10-22 12:10:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Fullen-1973" TYPE="STUDY">Fullen 1973</LINK> demonstrated caval filters were effective in reducing PE but not mortality in a quasi-randomised trial of 129 patients with proximal femoral fractures, over a 33 to 34 day period. Anticoagulation was not given in either arm. Mortality was 4/41 in the filter group and 14/59 in the control group (RR 0.41, 95% CI 0.15 to 1.16). Rate of pulmonary embolism in the filter group was 4/41, and 19/59 in the control group (RR 0.3, 95% CI 0.11 to 0.82). No details about long term complication rates were given.<BR/>
<BR/>The <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study demonstrated the efficacy of caval filters in preventing pulmonary embolism in a group of people with proximal DVT or PE and receiving concurrent anticoagulation, at eight years (hazard ratio 0.37, 95% CI 0.17 to 0.79 in favour of a filter) (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). At eight years, there was a significant increase in the rate of DVT in the filter group (hazard ratio 1.52, 95% CI 1.02 to 2.27) (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>Post-thrombotic syndrome was a common complication (defined as the appearance or worsening of oedema, varicose veins, trophic disorders, or ulcers) in both groups, affecting 68% to 70% of people in each study group. No data were collected on filter-related complications as the sample sizes were not powered to detect them.</P>
<P>The <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study included small subgroups of people with cancer, and used four permanent filter designs. It lacked statistical power to be able to draw any conclusions.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-10-22 12:14:14 +0100" MODIFIED_BY="[Empty name]">
<P>No firm conclusions regarding filter efficacy in the prevention of pulmonary embolism can be drawn from either of the RCTs.</P>
<P>
<LINK REF="STD-Fullen-1973" TYPE="STUDY">Fullen 1973</LINK> showed a reduction in PE in high risk people following a traumatic hip fracture who did not receive DVT prophylaxis. However, it was inadequately randomised; there were more people with fractures in the control group which could not undergo internal fixation, and the outcome assessors were not blinded. It also used a filter that was subsequently removed from clinical use because of its occasional fatal filter embolism risk and high late caval thrombosis rate (<LINK REF="REF-Greenfield-1992" TYPE="REFERENCE">Greenfield 1992</LINK>).</P>
<P>In the <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study, the group of people who received filters in the study varied significantly from the wider application in current clinical practice, notably those patients with DVT or PE and in whom anticoagulation has failed or cannot be administered. This limits the generalisability of the study's conclusion. In addition, the <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study used permanent filters. There is an increasing trend towards the use of retrievable filters in practice, although it would seem many of these are left in situ<I> </I>(<LINK REF="REF-Karmy_x002d_Jones-2007" TYPE="REFERENCE">Karmy-Jones 2007</LINK>)<I>. </I>The <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study also lacked statistical power to detect a reduction in the incidence of pulmonary embolism over shorter and more clinically significant time periods.</P>
<P>No recommendations can be made for other subgroups of people who might benefit from filters as they have not been studied in this or any other RCT. There are several large case series reporting long-term experiences of filters for various indications but none of these studies fulfilled the inclusion criteria for this review. These groups of people include those with cancer and pregnant women, with concurrent venous thromboembolism; patients with proven DVT or PE in whom anticoagulation has failed; patients with upper limb thrombosis and superior vena caval filters; those with supra-renal caval filters; and people with trauma who do not have established venous thromboembolism but have a filter inserted for prophylaxis.</P>
<P>The failure of the <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study to demonstrate a survival advantage was due to the older study population (mean age 73 years) with multiple other co-morbidities; the majority of deaths were attributed to cancer or cardiovascular-related causes. Pulmonary embolism accounted for seven deaths, but the <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study lacked statistical power to detect a difference in PE-related mortality.</P>
<P>The <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study did show an increasing incidence of DVT that correlated to the length of time the filter was in situ. The study demonstrated an increased risk of DVT in the filter group at eight years. Given the current lack of evidence in people who have a permanent filter inserted due to a perceived bleeding risk, observations from the <LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK> study suggest that consideration should be given to long-term anticoagulation when or if the risk of bleeding resolves. However, further data are required to confirm this observation. The placement of filters in people with major trauma without established DVT or PE is not as straightforward as it seems and continues to be a source of controversy and debate.</P>
<P>Retrievable filters have variable retrieval rates as reported in the literature, from 22% (<LINK REF="REF-Karmy_x002d_Jones-2007" TYPE="REFERENCE">Karmy-Jones 2007</LINK>) to between 88% and 100% (<LINK REF="REF-Imberti-2005" TYPE="REFERENCE">Imberti 2005</LINK>). The true rate of filter retrieval is not known as these figures are likely to reflect publication bias. Local rates of removal are influenced by the clinical situation, the experience of the individual interventionist, and institutional protocols. Drug-eluting filters have extended the recommended implantation period to 12 weeks, enabling the scenario in which the filter was indicated to resolve or diminish; before this their retrieval would be compromised. It is envisaged that retrievable filters may avoid the long-term thrombogenic problems seen with permanent filters but this remains to be seen.</P>
<P>There are no long-term clinical trials directly comparing the efficacy of permanent filters to temporary filters, nor comparing between different filter designs.</P>
<P>Superior vena caval filters are inserted for upper limb thrombosis; the majority of upper limb venous thromboses occur in the setting of an intravascular device within a central vein. Filters, being foreign objects within the body, potentially promote thrombosis. The superior vena cava is much shorter than the inferior vena cava, theoretically increasing the risk of clinically significant filter embolisation. Further information is needed before their placement in the superior vena cava is considered.</P>
<P>Filters have a relatively low rate of serious adverse outcome; these data come from large pooled case series and registry data of permanent filters, with one pooled series totaling over 3000 participants. Twenty year follow-up figures are available from another filter registry (<LINK REF="REF-Greenfield-1995" TYPE="REFERENCE">Greenfield 1995</LINK>). This information is subject to incomplete rates of participant follow up in a heterogeneous study population over varying time periods, and provides details generally pertaining to a single filter design. Thus, there is likely to be significant inherent bias in the conclusions based on this information. Despite the limitations of this registry, some insight into the safety profile of permanent filters can be gleaned: the mortality rate from filter insertion was 0.12%; migration occurred in 3% to 69% of patients depending on the definition of migration; filter migration is usually of little clinical significance. Perforation occurred at a rate of 9% to 24%; radiological features of perforation were common and in the majority of cases did not lead to any clinical sequelae. Inferior vena caval thrombosis occurred at a rate of 4% to 30%, but not all series had routine, follow-up Doppler examinations. It is unknown whether caval thrombosis reflects an efficient filter which has performed its task and trapped thrombus en route; or reflects in situ thrombosis due to altered blood flow from the mere presence of a filter in addition to a thrombogenic tendency inherent with any foreign object within the body, occurring in a group of people with a thrombotic predisposition. Thrombi may then propagate across a filter, with subsequent emboli from fragmentation of the thrombus beyond the filter. Small emboli can also pass between the filter struts or travel through a collateral circulation if this has developed. Recurrent PE in the presence of a filter, occurs at a rate of 2% to 5%; fatal PE rates are 0.7% (<LINK REF="REF-Hann-2005" TYPE="REFERENCE">Hann 2005</LINK>; <LINK REF="REF-Kinney-2003" TYPE="REFERENCE">Kinney 2003</LINK>). There are case reports of a second filter placed above the first to prevent further embolisation (<LINK REF="REF-Arbogast-1994" TYPE="REFERENCE">Arbogast 1994</LINK>; <LINK REF="REF-Hann-2005" TYPE="REFERENCE">Hann 2005</LINK>). Again, there is no evidence currently available to support this practice.</P>
<P>Smaller case series on retrievable filters are being collated; the largest series to date totals 169 participants (<LINK REF="REF-Stein-2004" TYPE="REFERENCE">Stein 2004</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-05 10:45:35 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-11-05 10:45:35 +0000" MODIFIED_BY="[Empty name]">
<P>No recommendations can be drawn from the two RCTs of filters included in this review.</P>
<P>
<LINK REF="STD-Fullen-1973" TYPE="STUDY">Fullen 1973</LINK> was inadequately randomised, had more people unable to have surgical fixation of their fracture in the control group, and the outcome assessors were not blinded. It has limited generalisability as it is now considered standard practice for DVT prophylaxis to be administered in people with traumatic hip fractures.</P>
<P>
<LINK REF="STD-PREPIC" TYPE="STUDY">PREPIC</LINK>s generalisability is also limited. This RCT also lacked statistical power to detect a reduction in the rate of PE at clinically significant time periods of less than eight years and used permanent filters. Retrievable filters are increasingly used when a filter is indicated. Filters are an adjunctive treatment with anticoagulation in patients with (or at high risk of) proximal DVT or PE. Anticoagulation remains the mainstay of treatment for venous thromboembolism provided there are no contraindications to this. Caval filters are associated with an increased risk of DVT in the longer term and this will likely influence the duration of anticoagulation. Caval filters are associated with a low rate of serious adverse events and, therefore, cannot be recommended for all people with venous thromboembolism. Their use is recommended to be restricted to certain high-risk situations until more information becomes available.</P>
<P>In the absence of evidence for other groups of people for whom filters are potentially beneficial and for the use of retrievable filters the American College of Chest Physicians Guidelines (<LINK REF="REF-Buller-2004" TYPE="REFERENCE">Buller 2004</LINK>) remain valid; the current accepted indications for filters remain as failure of, or contraindication, to, anticoagulation. Clinical judgment is required for other indications in which filters may be considered, such as for patients with venous thromboembolism and diminished cardiopulmonary reserve, those undergoing high-risk surgery, or those who receive thrombolysis for a proximal DVT.</P>
<P>It would appear to be prudent to scan the lower limbs to confirm the presence of residual thrombus before contemplating filter insertion.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-10-22 12:21:00 +0100" MODIFIED_BY="[Empty name]">
<P>Information regarding the indications, timing of insertion and removal, and short and long-term complications of permanent and retrievable filters is lacking.</P>
<P>Large randomised controlled trials are required in groups of people who have failed or have contraindications to anticoagulation, to confirm the efficacy of caval filters in this group; similarly in people who have cancer and concurrent venous thromboembolism, pregnant women who have PE or DVT, and in those with upper limb thrombosis and superior vena caval filters.</P>
<P>There are newer antithrombotic agents available and trials are required of these agents compared to filters with or without anticoagulation. Similarly, information regarding filter efficacy and complications in conjunction with other anticoagulation regimens (for example, low dose vitamin K antagonist protocols or long-term low molecular weight heparin-based protocols).</P>
<P>Large RCTs are also required to compare permanent versus retrievable filters; these should include subgroup analyses of various filter brands.</P>
<P>Outcomes should include rates of PE and DVT, mortality, post-thrombotic syndrome and its effects on quality of life; and filter-related complications: mortality from filter insertion, clinical filter embolism and perforation, and caval thrombosis.</P>
<P>The time duration of these trials should be at least two years to provide an indication of long-term complication rates.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-28 09:57:58 +0100" MODIFIED_BY="[Empty name]">
<P>Thanks to the Cochrane Review Group on Peripheral Vascular Diseases for assisting with the search for relevant articles, Mr Andrew J Wawrzyniak and Dr Karen Welch for their invaluable assistance, the University of Queensland Library for obtaining articles, and Dr Harry Bartlett (QUT) for statistical advice and input. Tim Young would like to thank Professor Alf Steinbeck for being a tremendous personal source of inspiration and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None declared</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-13 07:02:21 +0100" MODIFIED_BY="Tim Young">
<P>TY wrote the protocol and review with input from RH and HT.</P>
<P>TY, HT, RH searched for trials.</P>
<P>TY contacted relevant biomedical companies and clinicians involved with filters, and obtained full text articles.</P>
<P>TY, HT and RH selected and assessed trials for inclusion; and analysed, and interpreted results of these.</P>
<P>TY and HT independently extracted, entered, and analysed data in Revman.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-11-05 11:13:31 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-11-05 11:13:31 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-11-05 11:03:10 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Fullen-1973" MODIFIED="2009-11-05 11:03:10 +0000" MODIFIED_BY="[Empty name]" NAME="Fullen 1973" YEAR="1972">
<REFERENCE MODIFIED="2009-11-05 11:03:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fullen WD, Miller EH, Steele WF, McDonough JJ</AU>
<TI>Prophylactic vena caval interruption in hip fractures</TI>
<SO>Journal of Trauma</SO>
<YR>1973</YR>
<VL>13</VL>
<NO>5</NO>
<PG>403 - 10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-08-13 06:56:58 +0100" MODIFIED_BY="Tim Young"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PREPIC" MODIFIED="2009-09-02 11:39:38 +0100" MODIFIED_BY="[Empty name]" NAME="PREPIC" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Decousus H, Barral F, Buch-muller A, Charbonnier B, Girard P, Lamer C, et al</AU>
<TI>Eight-year follow-up of patients with permanent vena cava filter in the prevention of pulmonary embolism</TI>
<SO>Circulation</SO>
<YR>2005</YR>
<VL>112</VL>
<PG>416-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-02 11:39:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al</AU>
<TI>A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>7</NO>
<PG>409-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Decousus H</AU>
<TI>Eight-year follow-up of a randomized trial investigating vena cava filters in the prevention of PE in patients presenting a proximal DVT: The PREPIC trial</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>Abstract OC440</PG>
<EN>1</EN>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6457"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-04-21 15:16:40 +0100" MODIFIED_BY="Heather  Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Brasel-1997" NAME="Brasel 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brasel K, Borgstrom DC, Weigelt JA</AU>
<TI>Cost-effective prevention of pulmonary embolus in high-risk patients</TI>
<SO>The Journal of Trauma, Injury, Infection and Critical Care</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>3</NO>
<PG>456-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gosin-1997" NAME="Gosin 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gosin JS, Graham AM, Ciocca RG, Hammond JS</AU>
<TI>Efficacy of prophylactic vena caval filters in high-risk trauma patients</TI>
<SO>Annals of Vascular Surgery</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>100-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khansarinia-1995" NAME="Khansarinia 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khansarinia S, Dennis JW, Veldenz HC, Butcher LC, Hartland L</AU>
<TI>Prophylactic Greenfield filter placement in selected high-risk trauma patients</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Midy-1994" NAME="Midy 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Midy D, Pheline P, Baste JC</AU>
<TI>Antheor percutaneous filter endocaval filter. Multicentre evaluation based on 300 cases</TI>
<TO>Filtre endocave percutane antheor. Evaluation multicentrique a propos de 300 cas</TO>
<SO>Journal de Maladies Vasculaires</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>4</NO>
<PG>308-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-1996" NAME="Rodriguez 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez JL, Lopez JM, Proctor MC, Conley JL, Gerndt SJ, Marx VM et al</AU>
<TI>Early placement of prophylactic vena caval filters in injured patients at high risk for pulmonary embolism</TI>
<SO>The Journal of Trauma, Injury, Infection and Critical Care</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>5</NO>
<PG>797-804</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-1997" NAME="Rogers 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rogers FB, Shackford SR, Ricci MA, Huber BM, Atkins T</AU>
<TI>Prophylactic vena caval filter insertion in selected high-risk orthopaedic trauma patients</TI>
<SO>Journal of Orthopaedic Trauma</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>4</NO>
<PG>267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-1994" MODIFIED="2008-04-21 15:16:26 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Rosenthal 1994" YEAR="">
<REFERENCE MODIFIED="2008-04-21 15:16:26 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal D, McKinsey JF, Levy AM, Lamis PA, Clark MD</AU>
<TI>Use of the Greenfield filter in patients with major trauma</TI>
<SO>Cardiovascular Surgery</SO>
<YR>1994</YR>
<VL>2</VL>
<NO>1</NO>
<PG>52-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosner-2004" MODIFIED="2008-04-21 15:16:40 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Rosner 2004" YEAR="">
<REFERENCE MODIFIED="2008-04-21 15:16:40 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosner MK, Kuklo TR, Tawk R, Moquin R, Ondra SL</AU>
<TI>Prophylactic placement of an inferior vena cava filter in high-risk patients undergoing spinal reconstruction</TI>
<SO>Neurosurgical Focus</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>4</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webb-1992" NAME="Webb 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webb LX, Rush PT, Fuller SB, Meredith WJ</AU>
<TI>Greenfield filter prophylaxis of pulmonary embolism in patients undergoing surgery for acetabular fracture</TI>
<SO>Journal of Orthopaedic Trauma</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>2</NO>
<PG>139-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-11-05 11:13:31 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-2009" MODIFIED="2009-11-05 11:12:05 +0000" MODIFIED_BY="[Empty name]" NAME="Anon 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-05 11:12:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT00423683?term=NCT00423683&amp;rank=1) (accessed 3 Nov 2009)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2009-11-05 11:09:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PREPIC-2-2009" MODIFIED="2009-11-05 11:13:31 +0000" MODIFIED_BY="[Empty name]" NAME="PREPIC 2 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-05 11:13:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption (PREPIC2)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT00457158?term=NCT00457158&amp;rank=1) (accessed 3 Nov 2009)</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-11-05 10:13:22 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-11-05 10:13:22 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Arbogast-1994" NAME="Arbogast 1994" TYPE="JOURNAL_ARTICLE">
<AU>Arbogast JD, Blessed WB, Lacoste H, Gross WS, Gonde RL Jr, Welch RA</AU>
<TI>Use of two Greenfield filters to prevent pulmonary embolism in a heparin-allergic gravida</TI>
<SO>Obstetrics and Gynaecology</SO>
<YR>1994</YR>
<VL>84</VL>
<NO>4 part 2</NO>
<PG>652-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buller-2004" NAME="Buller 2004" TYPE="JOURNAL_ARTICLE">
<AU>Buller HR, Agnelli G, Hull HD, Hyers TM, Prins MH, Raskob GE</AU>
<TI>Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP Conference on antithrombotic and thrombolytic therapy</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126 (3 Suppl)</VL>
<PG>401-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Douketis-1998" NAME="Douketis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS</AU>
<TI>Risk of fatal pulmonary embolism in patients with treated venous thromboembolism</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>279</VL>
<NO>6</NO>
<PG>458-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gomes-2003" NAME="Gomes 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gomes MPV, Kaplan KL, Deitcher SR</AU>
<TI>Patients with inferior vena cava filters should receive chronic thromboprophylaxis</TI>
<SO>The Medical Clinics of North America</SO>
<YR>2003</YR>
<VL>87</VL>
<PG>1189-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenfield-1992" NAME="Greenfield 1992" TYPE="JOURNAL_ARTICLE">
<AU>Greenfield LJ</AU>
<TI>Evolution of venous interruption for pulmonary thromboembolism</TI>
<SO>Archives of Surgery</SO>
<YR>1992</YR>
<VL>127</VL>
<NO>5</NO>
<PG>622-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1575633"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Greenfield-1995" NAME="Greenfield 1995" TYPE="JOURNAL_ARTICLE">
<AU>Greenfield LJ, Proctor MC</AU>
<TI>Twenty year clinical experience with the Greenfield filter</TI>
<SO>Cardiovascular Surgery</SO>
<YR>1995</YR>
<VL>3</VL>
<NO>2</NO>
<PG>199-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hann-2005" NAME="Hann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hann CL, Streiff MB</AU>
<TI>The role of vena caval filters in the management of venous thromboembolism</TI>
<SO>Blood Reviews</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>179-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-11-05 10:11:05 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.0.2 [updated September 2009] <I> </I>
</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imberti-2005" NAME="Imberti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Imberti D, Ageno W, Carpenedo M</AU>
<TI>Retrievable vena caval filters: a review</TI>
<SO>Current Opinion in Haematology</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>351-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, McQuay HJ</AU>
<TI>Clinical trials: Is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karmy_x002d_Jones-2007" NAME="Karmy-Jones 2007" TYPE="JOURNAL_ARTICLE">
<AU>Karmy-Jones R, Jurkovich GJ, Velmahos GC, Burdick T, Spaniolas K, Todd SR, et al</AU>
<TI>Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study</TI>
<SO>Journal of Trauma Injury, Infection and Critical Care</SO>
<YR>2007</YR>
<VL>62</VL>
<PG>17-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kinney-2003" NAME="Kinney 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kinney TB</AU>
<TI>Update on inferior vena caval filters</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>425-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirilcuk-2005" NAME="Kirilcuk 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kirilcuk NN, Herget EJ, Dicker RA, Spain DA, Hellinger JC, Brundage SI</AU>
<TI>Are temporary inferior vena caval filters really temporary?</TI>
<SO>American Journal of Surgery</SO>
<YR>2005</YR>
<VL>190</VL>
<PG>858-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norris-1985" NAME="Norris 1985" TYPE="JOURNAL_ARTICLE">
<AU>Norris CS, Greenfield LJ, Hermann JB</AU>
<TI>Free-floating iliofemoral thrombus: a risk of pulmonary embolism</TI>
<SO>Archives of Surgery</SO>
<YR>1985</YR>
<VL>120</VL>
<PG>806-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Radomski-1987" NAME="Radomski 1987" TYPE="JOURNAL_ARTICLE">
<AU>Radomski JS, Jarrell BE, Carabasi RA, Yang S-L, Koolpe H</AU>
<TI>Risk of pulmonary embolus with inferior vena caval thrombosis</TI>
<SO>American Surgeon</SO>
<YR>1987</YR>
<VL>53</VL>
<PG>97-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stein-2004" NAME="Stein 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stein PD, Alnas A, Skaf E, Kayali F, Siddiqui T, Olson RE, et al</AU>
<TI>Outcomes and complications of retrievable inferior vena cava filters</TI>
<SO>American Journal of Cardiology</SO>
<YR>2004</YR>
<VL>94</VL>
<PG>1090-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-2006" NAME="Yusuf 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al</AU>
<TI>Comparison of fondaparinux and enoxaparin in acute coronary syndromes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>14</NO>
<PG>1464-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16537663"/>
<IDENTIFIER TYPE="OTHER" VALUE="ClinicalTrials.gov number, NCT00139815"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-04-21 15:49:13 +0100" MODIFIED_BY="Heather  Maxwell">
<REFERENCE ID="REF-Young-2007" MODIFIED="2008-04-21 15:49:13 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Young 2007" TYPE="COCHRANE_REVIEW">
<AU>Young T, Aukes J, Hughes R, Tang H</AU>
<TI>Vena caval filters for the prevention of pulmonary embolism</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-04-21 15:49:13 +0100" MODIFIED_BY="Heather  Maxwell">
<IDENTIFIER MODIFIED="2008-04-21 15:49:13 +0100" MODIFIED_BY="Heather  Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006212.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-11-05 10:53:53 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-11-05 10:51:15 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-11-05 10:47:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fullen-1973">
<CHAR_METHODS MODIFIED="2009-10-22 20:34:19 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: A single centre study.</P>
<P>Country: United States.</P>
<P>Follow up was adequate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-22 20:28:04 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 129 participants with proximal femoral fractures. </P>
<P>Age: Average age 69 and 67 years (filter and control group respectively). </P>
<P>Sex: Gender distribution not stated. </P>
<P>Inclusion criteria: Proximal femoral fractures were invited to participate in the study.</P>
<P>Exclusion criteria: Refusal to participate in the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-22 20:34:30 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Permanent caval filter.</P>
<P>Control: No filter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-05 10:47:48 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes.</P>
<P>1. Mortality.</P>
<P>2. Pulmonary embolism.</P>
<P>Secondary outcomes.</P>
<P>1. Complications from filter insertion.</P>
<P>Outcomes assessed when clinically indicated and at discharge.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-22 20:26:37 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad score 2/5.</P>
<P>Anticoagulation was not used in either the intervention (filter) or control arm.</P>
<P>Not an intention to treat analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 10:50:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PREPIC">
<CHAR_METHODS MODIFIED="2009-11-05 10:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: Multicentre study; randomised control open trial using a 2x2 factorial design.</P>
<P>Country: France.</P>
<P>Intention-to-treat analysis.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 10:49:34 +0000" MODIFIED_BY="[Empty name]">
<P>Number: 400 participants.</P>
<P>Age: 73 +/- 11.</P>
<P>Sex: 64% were male.</P>
<P>
<BR/>Inclusion criteria: Age &gt;18 with documented proximal DVT or PE, and considered high risk for pulmonary embolism.</P>
<P>Exclusion criteria:</P>
<OL>
<LI>previous filter;</LI>
<LI>contraindication or failure of anticoagulation;</LI>
<LI>curative anticoagulation &gt; 48 hours duration;</LI>
<LI>indication for thrombolysis;</LI>
<LI>short life expectancy;</LI>
<LI>allergy to iodine;</LI>
<LI>hereditary thrombophilia;</LI>
<LI>severe renal or hepatic failure;</LI>
<LI>pregnancy;</LI>
<LI>likely non-compliance.</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(Permanent) caval filter vs no filter<BR/>LMWH vs unfractionated heparin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-05 10:50:59 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes.</P>
<OL>
<LI>Pulmonary embolism.</LI>
<LI>Mortality.</LI>
<LI>Deep venous thrombosis.</LI>
</OL>
<P>Secondary outcomes.</P>
<OL>
<LI>Bleeding.</LI>
<LI>Post-thrombotic syndrome.</LI>
<LI>Filter-related complications.</LI>
</OL>
<P>Outcomes assessed at 12 days, two years, eight years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-22 20:33:29 +0100" MODIFIED_BY="[Empty name]">
<P>Study had low power.</P>
<P>Jadad score 3/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DVT: deep vein thrombosis<BR/>LMWH: low molecular weight heparin<BR/>PE: pulmonary embolism</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-04-21 15:15:37 +0100" MODIFIED_BY="Heather  Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Brasel-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cost-effectiveness analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gosin-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prospective interventional cohort with historical control; selected high-risk people received filters; no data on baseline characteristics of the interventional cohort and the control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khansarinia-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prospective interventional cohort with historical control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Midy-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodriguez-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prospective interventional cohort with historical control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rogers-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prospective interventional cohort with historical control; selected high-risk people received filters; interventional and cohort groups unmatched according to baseline characteristics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosenthal-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosner-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prospective interventional cohort with historical control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Webb-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Selected high-risk patients received filters; no data on baseline characteristics of interventional and control groups; people received concurrent DVT prophylaxis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>DVT: deep vein thrombosis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-11-05 10:53:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-10-22 20:42:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anon-2009">
<CHAR_STUDY_NAME MODIFIED="2009-10-20 12:22:55 +0100" MODIFIED_BY="[Empty name]">
<P>A randomized control trial of anticoagulation and inferior vena cava filters in cancer patients with a venous thromboembolism.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-10-22 20:40:54 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, open label, active control, parallel assignment, safety/efficacy study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-20 12:24:58 +0100" MODIFIED_BY="[Empty name]">
<P>Cancer patients, over 18 years of age, acute radiographically confirmed denovo DVT or PE.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-20 12:22:53 +0100" MODIFIED_BY="[Empty name]">
<P>Arixtra (fondaparinux) alone vs. arixtra with filter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-22 20:42:01 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Death due to any cause, event free survival.<BR/>
<BR/>Secondary outcomes: Occurrence of pulmonary embolism, major bleeding, thrombophlebitis, cellulitis secondary to IV filter, thrombosis of the IVC filter and quality of life.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-08-28 09:38:41 +0100" MODIFIED_BY="[Empty name]">
<P>January 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-08-28 09:54:48 +0100" MODIFIED_BY="[Empty name]">
<P>Myra Barginear, MD </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-10-20 12:21:26 +0100" MODIFIED_BY="[Empty name]">
<P>NCT00423683</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-11-05 10:53:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PREPIC-2-2009">
<CHAR_STUDY_NAME MODIFIED="2009-10-20 12:24:07 +0100" MODIFIED_BY="[Empty name]">
<P>PREPIC 2 : Interruption of inferior vena cava by a retrievable filter for the prevention of recurrent pulmonary embolism : a randomised, open label study.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-10-22 20:43:00 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, open label, active control, parallel assignment, safety/efficacy study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 10:52:39 +0000" MODIFIED_BY="[Empty name]">
<P>Age: &gt; 18 years.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Informed consent.</LI>
<LI>Acute symptomatic pulmonary embolism; and</LI>
<LI>Deep or superficial vein thrombosis; and</LI>
</UL>
<P>At least one of the risk factors below :</P>
<UL>
<LI>More than 75 years old.</LI>
<LI>Cancer (excepting locally cutaneous cancer).</LI>
<LI>Known chronic heart failure treated.</LI>
<LI>Chronic respiratory insufficiency treated.</LI>
<LI>Bilateral deep vein thrombosis.</LI>
<LI>Ilio-cava thrombosis.</LI>
<LI>Ischemic stroke &gt; 3 days and &lt; 6 months, with lower limb deficit.</LI>
<LI>Cardiac repercussion of pulmonary embolism assessed by echocardiography or increasing troponin I or T, or Brain Natriuretic Peptide (BNP) or proBNP.</LI>
</UL>
<P>Exclusion Criteria:</P>
<UL>
<LI>Contrindication to an anticoagulant treatment or recurrent thromboembolic event despite adequate anticoagulation.</LI>
<LI>Vena cava filter already inserted.</LI>
<LI>Filter insertion impossible due to caval thrombosis.</LI>
<LI>More than 72 hours pre-randomised treatment with therapeutic dosage of anticoagulant therapy.</LI>
<LI>Non carcinologic surgery within three months prior randomisation.</LI>
<LI>Carcinologic surgery within 10 days prior randomisation.</LI>
<LI>Hypersensitivity to contrast media.</LI>
<LI>Access port in place or programmed within 3 months.</LI>
<LI>Woman who are child bearing.</LI>
</UL>
<UL>
<LI>Life expectancy &lt; 6 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-22 20:49:42 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: optional/retrievable filter.</P>
<P>Control: No filter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-22 20:50:43 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: at three months, combined criteria including recurrent PE confirmed by objective tests and fatal PE confirmed by autopsy and death which cannot be attributed to a documented cause and for which PE/DVT cannot be ruled out.<BR/>
<BR/>Secondary outcomes:</P>
<P>Recurrent pulmonary embolism, fatal or not, at six months (combined criteria including recurrent pulmonary embolism confirmed by objective tests and fatal PE confirmed by autopsy and death which cannot be attributed to a documented cause).<BR/>Current or new symptomatic DVT confirmed by objective tests.<BR/>Mechanical complication of filter (migration, tilt, transfixion) and or puncture site hematoma, and/or local or general infection due to filter.<BR/>Filter thrombosis.<BR/>Filter retrieval failure.<BR/>Total death.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-08-28 09:54:39 +0100" MODIFIED_BY="[Empty name]">
<P>July 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-11-05 10:53:53 +0000" MODIFIED_BY="[Empty name]">
<P>Patrick Mismetti, MD PhD, Karine Rivron Guillot, MD</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-10-20 12:19:27 +0100" MODIFIED_BY="[Empty name]">
<P>NCT00457158</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-11-05 10:51:15 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-11-05 10:51:09 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 10:48:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fullen-1973">
<DESCRIPTION>
<P>Randomisation based on odd or even hospital number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 10:51:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PREPIC">
<DESCRIPTION>
<P>Randomisation was based on a centralised computer system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-11-05 10:51:09 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 10:48:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fullen-1973">
<DESCRIPTION>
<P>Open study design; participation in filter group based on consent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 10:51:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PREPIC">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-11-05 10:51:11 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Pulmonary embolism</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 10:48:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fullen-1973">
<DESCRIPTION>
<P>Open study design; blinding of outcome assessors not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-05 10:48:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fullen-1973">
<DESCRIPTION>
<P>Open study design; blinding of outcome assessors not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-05 10:51:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-PREPIC">
<DESCRIPTION>
<P>Open study design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-11-05 10:51:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-PREPIC">
<DESCRIPTION>
<P>Open study design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-11-05 10:51:14 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Pulmonary embolism</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-26 01:11:49 +0100" MODIFIED_BY="Tim Young" RESULT="YES" STUDY_ID="STD-Fullen-1973">
<DESCRIPTION>
<P>Cause of death and numbers reported. Follow-up complete as in-hospital population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-07-26 01:13:44 +0100" MODIFIED_BY="Tim Young" RESULT="YES" STUDY_ID="STD-Fullen-1973">
<DESCRIPTION>
<P>Definite, probable and possible pulmonary embolism rates reported. Blinding of outcome assessors not stated. Use of chest radiography in diagnosis of PE is inaccurate. Not stated whether all patients had routine imaging, or only when clinically indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-26 01:14:43 +0100" MODIFIED_BY="Tim Young" RESULT="YES" STUDY_ID="STD-PREPIC">
<DESCRIPTION>
<P>Negligible losses to follow up (only 4 of 400 participants). No missing outcome data. Causes of death reported. Mortality reported at 12 days, two years and eight years.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-11-05 10:51:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PREPIC">
<DESCRIPTION>
<P>No missing outcome data. Pulmonary embolism reported at12 days, two years and eight years.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-11-05 10:51:15 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-26 01:29:58 +0100" MODIFIED_BY="Tim Young" RESULT="UNKNOWN" STUDY_ID="STD-Fullen-1973">
<DESCRIPTION>
<P>Protocol brief. Mortality, PE and filter complication outcomes documented. Rates of DVT not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 10:51:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PREPIC">
<DESCRIPTION>
<P>Primary and secondary outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-06-30 10:38:39 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-02-04 11:45:09 +0000" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2009-11-05 10:51:16 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="ty21091.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2009-11-03 16:08:23 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram of search results</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a
HBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIy
MjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAMAA1YDASIA
AhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQA
AAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3
ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWm
p6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEA
AwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSEx
BhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElK
U1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3
uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+iii
gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKA
CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK
KQjI4JFLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcv8AEb/km/iP/sHTf+gmuorl
/iN/yTfxH/2Dpv8A0E0AbGhf8gDTf+vSL/0EUUaF/wAgDTf+vSL/ANBFFAGhRTSMgjOM+lOoAKKK
KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooo
AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigA
ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5f4jf8k38R/wDYOm/9BNdRXMfECJ5vh34i
RF3MdPmOM46ISf5UAa+hf8gDTf8Ar0i/9BFFGhf8gDTf+vSL/wBBFFAGhRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSDOTkjHagBaKKKACiiigAooooAKKK
KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooo
AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigA
ooooAKKKKACiiigAooooAKKKKACiiigAooooAKwvGn/IieIf+wZc/wDopq3awvGn/IieIf8AsGXP
/opqALuhf8gDTf8Ar0i/9BFFGhf8gDTf+vSL/wBBFFAGhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFA
BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRTScAnnj0oAdRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAFFFFABWF40/5ETxD/wBgy5/9FNW7WF40/wCRE8Q/9gy5/wDRTUAXdC/5
AGm/9ekX/oIoo0L/AJAGm/8AXpF/6CKKANCiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooo
AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimgADgAd6AHUUUUAFFFFABRRRQAUUUUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAVheNP+RE8Q/8AYMuf/RTVu1heNP8AkRPEP/YMuf8A0U1AF3Qv+QBpv/XpF/6C
KKNC/wCQBpv/AF6Rf+giigDQooqGQlUYqrEgZCjGT7DPFAE1FJ29KWgAooooAKKKKACiiigArM1r
VbXRNIu9TvJAltbRmR274HYe5OAPc1p1j+JX09PDeoHV0EmneSRcg9PLPDH8Ac/hQBFba1cPqVvY
XWk3do08TSpKzxvHhcZUlWJDfMOMY64JxW7XmWl2+p+FNf0/RrDVP7Y0W9t52sopyHmsyiFlw4+9
EeF56EqPrR8P6nZTWunay/iRv7Rhs5jqVnbxMbh2EZL+cjO20ow+UlQASFGAwFAHrdFeM2WpWpv4
kh1ZVguvDk8hEd+WlkkUxFJJGBH74hmJ2gHqMsBVyzlt9G8P+EL+91G9On6r9n/tW6uLtmQMLdvL
DEnCKXKhsYB2qGyCcgHfavrg0rUtItDayyrqNybZZlZQsTBGcbgTuOQrYwMcckcZ3K8v1O3025Tw
1ZWWp3N1YnxA6rMtxuwGt5mKRyKc7V3bQQcrgjORxv8AgXbFBrlhHcTSwWOrTQQrNMZGjTajBcsS
2AWbGTmgDsaK8qdbuLUPHup2V9eveaU7NZxC5kkRS1qpIKMSGwxJCngMOMCixNvPZ3l5pfje3KXe
mMuyESEQsSoFxJumdkZSdrH5TySeVyAD1WsfX9V/sHRLzVXt57iO0heaSOEqGKqMk/MQOACeufQH
pXnN/c3Nnoeri5juNM1CxvdOaXyL13ttrTKpeJiQVVlLblYccE9c1Z1vU4rlPiXAl8k0SaOrRxib
cqkwyhioyQOQAcd+tAHoceoW0l3bwAgXM8BnWI/eCDaCT9Cyj8Tjoa0q8ykTS7T4jWV9eNb20smg
blnZVDGRXUArn7zBc4AB47VZ8EO9rq62F0sM9xJpyzR6lZTs8V3GGC7pFblZSSDnkNlueMUAdNq+
svp95a2dpb/ar+5jlligaTywyxhd3zYIByygDHJbqBk0nhrXz4isJ7ptPmspILmS2eCZlZldDtbJ
XI65HBPSsPWrPTp/ir4d86CBp2sbx2DAFiVMO0n6YbH0Nc9HfvBpM6pMy2M3jCeC/kR8bYmlYgEg
/KrNsBOR8rc8GgD1yivMr3w/casfF+h2E0n2KJYZtP2uwFvd7WLRq2fu8ISvQeYemaorqV3daja6
7Z2EkVl4is/7OWMqxEV1jIkZT0XPmKcDkRA5IYUAet1hNrjL4pbQvsM5YWTXiz7l2vhgu0DOc5bq
cdPxqj4pmn8P+A7ptO84G1iRN6ks8cW5Q7gnJLKhZs88rXPWX9hH4kx2+magptb3QZd3k3zHJ8xC
GU7shipY7gc8E+poA77Tbme9062ubm0ks7iWMO9u7AtExHKkjgkVerx7SdVtrvwz4Ttb6+Bmm0mW
Vxe3ZjhflV8xm+80inO0A8bmOQQMyaX4giu9B8GyapqMd7by2EguYTdKshnUR4kYsyhtoJBBOQzq
2DgkAHrtFeUf2XL5Xgqxu9XvnkvLi5Wd4tUkfzE8iUhdwbBIAVcr3zjGc1R8R3lhY3N61tqCR32m
X9hAJbyctdBVaFWCD5SsRViWZtwYs3HINAHstFeJ66LGbSvH2pxajcNc2N4s1m63r7YmMUTKyANg
ksWHfjgYHB7TSkttN+I97Z2VzI0V1pkVyyPcNKGk81wX5JIJUr6A8Y70AdxRRRQAUUUUAFFFFABR
RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAVheNP+RE8Q/9gy5/9FNW7WF40/5ETxD/ANgy5/8ARTUAXdC/5AGm/wDXpF/6CKKN
C/5AGm/9ekX/AKCKKANCiiigAooooAKKKKACiiigAooooAKaVDDBAI9DTqKAKdtp9nZNI1paQW7S
HLmKMKWPqcDmljtLWGeWaK2iSWXmR1QBn+pHJ/GrdFAFFdNsljWIWduIlBCoIhtUHrgY796c1hZy
Whs2tIDasMGExqUI9CuMVcooApDTrIJAn2K32Qf6lfKXEf8AujHH4VLDbW8G4wwRRFjk7EC5Pvjr
ViigCnDZ21s8jW9tFE8zbpGRApc4xliByfrUaaRpsUU8Uen2qRXBzMiwKFkPqwxz+NaFFAGdFpOn
W9pJZwWFrFay5DwJEqo2Rg5UDByPWh9I014DC+nWjQlVGxoFK4X7oxjGB29K0aKAKkdpbRRxxpbx
KkS7I1VAAi4xhR2GAOBToLS3tgRBbxRBuojQLn64qzTCQCMkDPA96AK0ljaSSi4e1haYEESGMFgR
0OcZ4pUsbSJHSO2hRJBh1WMAMPcY561booAghgit4lihiSKNfuqihQPoBSiNAFGxQFOQMdD7fmam
ooAaQCCCAQeoNVUsLNEZEtYEjIIKrGACD1BGKuUUAUv7PsSIv9Ct/wBy2+L90v7tvVeOD7iuf1vw
pLf3lrNZTafHDDE0Rsr2wE9udzBiwUMpVsgc55rraKAMDSPDlnpMO0Wdm0xkMpaG2WJVYgD5VGdo
49SepJJNa7W8JLM0UbM+NxKglsdM+uKsUUAVGsrRwd1tC2euYwc9/ShLO3icPHBErKAAyqAQAMDn
6cfSrdFABRRRQAUUUUAFFFFABRRRQAUUUUAFIM5OSMdqWigAooooAKKaRyOSP606gAooooAKKKKA
CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK
KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsLxp/yIniH/ALBlz/6Kat2s
Lxp/yIniH/sGXP8A6KagC7oX/IA03/r0i/8AQRRRoX/IA03/AK9Iv/QRRQBoUUUUAFFFFABRRRQA
UUUUAFFFIBgdSaAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigAooooAKKKKACiiigApoOSfb2p1FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVheNP8AkRPEP/YMuf8A0U1btYni2Frj
wbrkCFQ0mnzopboCY2HNAFvQv+QBpv8A16Rf+giijQv+QBpv/XpF/wCgiigDQooooAKKKKACiiig
AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKyde1mHw/oV7qtzFJJDax
mR0ixuI9BkgZ59ayP+Er1kk/8UPrnH/Ta1/+PUAdbRXJDxXrJ/5kfXAOf+Wtr/8AHqafF+rDJPgf
XePR7Y56/wDTWgDr6K5MeKtUIGPBOvEnkgtbDA/Gb9KbF4q1N1/5EvXR8xHL23UHB/5bdODz3/Gg
DrqK5SPxbfuP+RP8QDPIBW3Hc9czcdKD4vulA3eEPEfPXEMJwfwloA6uiuT/AOE1uMgf8If4m5/6
dov/AI7SL4w1CUEW/gvxCzL1EiwR/kWl5oA62iuT/wCEq1nJH/CEa1xnnzrX/wCPUp8U60P+ZH1s
/Se1/wDj1AHV0Vyf/CV61/0I2t/9/rX/AOPUn/CV6yAc+B9c49JrU/8AtagDraK5IeK9ZI/5EfW/
+/1r/wDHqQ+LdaB/5EbXO3/LW1/+O0AddRXJHxZrQHPgbXPwltT/AO1aj/4S/WDjPgbXvmGR89t+
v73j6GgDsaK4/wD4S/Vyu4eB9cx7yW2emenm5pU8Xaoyhz4K14KSP4rYnpnp5uaAOvorkz4uu1YA
+DvEXPcRwnp1/wCWv/66a3i3UnYiDwVr7hTgl/s8fPtul5+ooA66iuT/AOEr1r/oRtb/AO/1r/8A
HqP+Er1r/oRtb/7/AFr/APHqAOsorkv+Es1nOP8AhB9c/wC/1r/8epP+Eu1nbn/hBtcxjP8ArbbP
5ebQB11FcifFus4OfA2u5HpJan/2rTT4w1gA58Da7xjo9sf/AGrQB2FFcfJ4u1dYyx8D69hRyFe2
J/ACXJ/CkXxhqropXwRr2WIADNbqe/XMvHTv60AdjRXIDxlqWSG8E+IBgZGPs5zxnH+toTxdqLls
+C/EChTgki35+g83kc9RQB19FciPFt7wf+EM8Q4P+xBx07eb6H9MUg8U63Jl7fwVqrRAHaZri3iY
kH+6X4HvQB19FcsviTXdvz+C9UBxnC3Vq3Pp/rRUY8Va8WVT4G1cc4Y/aLXA+n73mgDraK5Q+Kda
Gf8AiiNaOPSe1/8Aj1V5/GOqWkElzceCtaSGJGkdzLbHaoGSeJfQUAdnRVOxuVvLCC6RSFmjWRVJ
BIDAHHHHerlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFA
BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVmeIf+Rb1T/r0m/wDQGrTrM8Q/8i3qn/XpN/6A
1AD9C/5AGm/9ekX/AKCKKNC/5AGm/wDXpF/6CKKANCiiigAooooAQjI6kUtFFABRRRQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByXxM/wCSa69/17H+Yrra5L4mf8k117/r2P8A
MV1tAGVqeu6Vo6o2p6ja2YkJCefKqFiOuATziprPUbLUoWmsLuC6iVtrPBIrqGwDjIOM4IP4ivMv
H9h4nt/G9v4n8ItDe31jZLDdac67mELO5VgpI3BirD5SG+UYzk4xLL4oQWPhKzOiaZ9g1HVNYeC4
ikQyJbyHaZGRRgn7ykKehJHOKAPd6K8juPHfi+y0Sxk1HT4tOMupPaTXtzAysYgFKSJAW3MzZPyr
u5UgDkYzf+Fr+In+E0XiuKLThfRXv2WZJIWKSLjggBgVPIzyR9KAPbqzLrWNMsb2CzutRtLe6uCB
DBLOqvIScAKpOTk8cd6831Hxr4y0I6XYaymj299r18kNlNbq7x20R2hywJG5gXXAyATu5xiud8cT
eK5r3wKdas7CDWo9baK2YHMUoDxbHYKzFQT1AOcDoOlAHvtFcH8OPFupeKItYg1VLYXWmXz2pktk
ZVcDvhiSOQe/pXNeJfiB4ih1zxRHpclrDbeHYIpTFLDv+0lmG4McgqME4xzkDnrQB6RrHiTRtAjj
l1bUbaySUkJ58gUsRjOB1OMjPpV/7VB9j+1+fH9m2eZ524bduM7s9MY5zXhesZ8afFrwbLcyQvZa
ppguEtpLfcsUTRuXjY7huJKsA2BjcODjnX+PdzPp3hPRtJtCbbTJ7kRT+V8qhFUbUwP4epx/sigD
0KLx74TmleOPxHpjMpxgXC89Pu8/N1HTNEnjrwpbzyQS+IdNSWMlXRrhQVI6gjPGKdeeE9DvvDsW
iPZImnxBPIWIAGIqQVKnHByBz3yc5ya8Y8RX2qaT8ZPG15pFostymkZLbwpiUxwbpBkfMVHO3/8A
UQD2eXxr4ZhtLe7l17TktbgsIZmnUI5U4YBs4OD1q1e+JdF0/wAg3mrWVv8AaF3QGSZQJRjOVOfm
H0rj/GHhrRtR0KLwzbMIYJ9XTz0hI3QvIrPkDoOoIHoa4XwtqGr+HvFek/D3X4nmNnqK3Gn3TKCD
EEk6E/wnII7qcqenAB6+fHfhIStEfEukq6khla7QEEdQcmnHxn4YEKSnxDpYidyiObtNpYAEjOcZ
AYHHuK8u+LGk2Ok6l4Cs7C1SGAamx2qMklniJJJ5JJJPNXPjhpdlpXgC4kt4AjXurxTyAYAMnlFS
QMcZVBnGOcnPYgHqNh4h0bVJ2g0/V7C7mUZMcFyjsB64Uk4q1cXNvZxo880cSu6xqzsACzEBVGe5
JAA968R026/4Sr43aSHtF0W40W0AeKZ/312ApPy7RtK4bPXlSTz0Fv426y93G2l2WpLbS6Qsd+6g
kNLMWARVPYqu5z9V6UAewX+q6fpUKy6jfWtnEzbVe4mWME+gLEc0tjqdjqdv9p0+7gu4ckeZBKsi
5HUZUkZrzLxtr8Xif9nq61lQrG5ggMijkJIJUVh7YYGut8G3ltp3wu8P3N26W8CabblnJwBlFAP1
JI/E0AddVC01OxvpbmK0uoZntpPKnVHB8t+6tjofauY+IPi228JaTAJbwWcuoSm3jumjZ1txjLSE
KCSQOgA5YjPGSPJfh9460nwn4V8RMt6xnm1YLbzSxu4VZAQsr4GSAFZiPvHGMc0AfQEOqWFxeXdr
FewPPabftMauCYdwJXcP4cgE8+lUtO8XeHtWvBZ6brdheXJBIignV2IAyTgGvDfAMkmuzfELR/D+
rrPqOplXtbq9DqJoQ7LJIxCkglZBxgHLDjAOOi+GtrceGfHMvh/XPDun2mqSWjSW+oWS4EsYYbgc
HGCR1AUjbgjkUAe20V5j498U+J9E8ZeH9J0KSycatujEd1GdqMpA3Fgc4w3IA/h45NYmo+OfHGna
rB4blhspNajsZLuU2ts86zvubZEqgjau0Lubtz+IB7TRXj83jfxpe+M7Dw7YQabp817pYvDHdwO0
kMm1tyN8453KcHHRgSDUOkfFLV/Emn+GLO2jt7TVNUu5ra5naMvHEIQrMyruGSQy8EkDmgD2akJA
GSQB714dd/FrxDH8PV8QQQWAvrfVG026ieJjFKdu8OuGDLxgEEn8Kj8dap4+tBolhrd5pVtFf6ui
KtlE7AqrIy7iWBKhj90YJ29aAPdqK8au/HPiSw+J1v4d1S8htoJri3jgYWYENyhwJCrEsyszHaBk
gcg4PNey0AFFFFABWT4l/wCRW1j/AK8pv/QGrWrI8TZ/4RXWMHB+xTc/8AagBfD20eHNMCBgotIg
oYEHGwdQeRWtVDRiDoenkEEG2jwR/uir9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVmeIf+Rb1T/r0m/9
AatOszxD/wAi3qn/AF6Tf+gNQA/Qv+QBpv8A16Rf+giijQv+QBpv/XpF/wCgiigDQooooAKKKKAC
iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5L4mf8k117/r2P8xXW
1yXxM/5Jrr3/AF7H+YrraAOZ1Dwqt5r39tW+rajYX5t0tt1syFCiszYZGVlY5c8kcYGMc5x9R+Fv
h/U/Dz6TcC53tdNeG+Djz2nb7zlsY54GMAcDjgGq3jDx7JofjbT/AA619Z6VDcWhuG1C7haVSxYq
sYAZQv3SSxOOnStvTPEFzaaLPfeKLiwtkW5Mcc8IKxTIduxl3MS27JIAz1xzjJAMi++Fek6jHphu
9S1h7qxuDcG9N0fOmchRlmI4wEQAjBAX8arD4O6Mvhafw2uq6sNPku/tewPGdrAEBRlDxyCe5wK6
x/F2gJpsWptq9oLKZykcvmjDuOqgdSRg5GMjFRzeN/DMGlwapLrVounzuUiuA+VZh1XI6EehoAqe
KfAeneLtGtLDU5rjfZlWhuoiqyq4ABbpt5xyMY6Yxis2++GNrfPpkk2u608+m3H2qKeWZJHab5cM
xZT0CKAowOOnJJ3l8a+G5La5uU1uxa3tpFhlcTghXPRfdjg4AznBrlvFHxIGlXvhefSbvSrnRtVu
xb3E75PlKHUMwYMAuFY8MOMc+lAG94S8E23hC51GW21C9ujqE3nzLcbMCTJJYbVBGc9OnFQ618Ot
H1zUr29lkvLdtQiSK+jt5FVbpUZWXdlSQflAypU4rodJ1vTtctjc6Xew3kAYoXhcMAw6g46Hp+dZ
+p+MPD2iX/2HUtVgt59ql0bJ8tWOAzkAhQSRyxA5oAoy/D/Tm8Uadr0V1ewXGmwpb2kUTIIoolBX
YFKkkEM2cnPPBGBjZ13QdN8SaXLpmq2q3FtJztPBUjoVI5Uj1H9a4Lxt4+1e38a6Z4S8OTWMF3cx
eY9zdIzrvIJSMYHAOBlsH7w6YNaHjvxrf+DdF0SSdYYri+nSC7vPLaWK24BdgoILdyoz0B+lAGpY
+BYbaK1t7nWtZ1C0tXVobS5nXYu0grnaqlwpAIDEjgcVAPhxZp4nvPEcOt6xHq10nlyzK8JBXCjA
UxEAYUDp2qPR/FE8a32paprOm3vh6OCJrfUrWMqCxZgyyAM2GGFzjA5HAPFa+l+NPDmt6kLHTNZt
bm5ZPMWNG5Ze5XPBxzkDkYOaAM+18A29rGqR67q7Ot+2pyTO8TPNMVVQWLIRtCrgAADk+gxtap4c
0/VNU0zUriI/a9NlMsEqYDDIIKnjlTnOPUCorLxboF7qz6TbavbTXykgxK3UrncAejEY5AJI71Tf
x34duIb5LHXNPe5toHk+ZyVG3I3cfeUEclc4waAGeKPAVj4tv9Pu77UL6JrB/Nt0gaMKj5BLcoST
lV6kjjpT/Ffgm08YaRBpep6hfrbxOrt5JjUzMBgMx2devC4HPTgYq6D4zgPguw1PxDqemi5uFlJa
yZmSTYzbti8s21Vy2AQMHtWX478d3WkaLoeseHryyurLUL1bZmZPMDKwJyrBhgjaQQQeT2xQBpan
8ONM1S+03UnvtRi1XTgFhv4HRJWAbIDALtbAJHQZBOc5q7pnhE6da6zB/bOoXLaq5lmluBEzK7KF
LL8gGMBQFIKgKAAOaztM8aIfEPiRdS1TSo9I01o/KZHIljJ+VhKD33cD1PTNbqeLvD0mlTaqur2h
sIZPKkn8zCq+Adv+98w4680AcnB8ILG08L3nhy317VxpV3IJJYWaFuQQeGMeVyVXOPT65vQfDcRa
Xp+lP4k1iTTLF43jtGEIVgjBlVisYZhkDgntW5P4x8Pw6TFqrarbmyll8mORCXLyZxsVVBYtx90D
Ncx8N/GWpeKtY8TW13NbzWum3Kw2skUJjZ1LSDcwJ6kKOMDFAHf3Fpb3SBLiCKZVOQsiBgD681z/
AIf8C6L4bhvobSJpkvbhrmRbgK4Vj2XCjAHYVzGv+LPEln8WNL8J2V5ZJa6lbm4WWS0LtFjzPl4c
Bv8AV9eOvtVrwP46vtZ1fxJpOtCzDaHKVe/twUidQWBLBidpG0nrjr6cgFl/hdogh19IJ763fW5F
klkhkVTCVYsBHhRgZPIOcgD0rY0TwpDpFxHeT399qV7FB9mjur1lZ0izuKjao6kDJOScDmpLHxj4
d1G0urq11i2kgtFDzyM+0Rqc4Zt2PlOOD0Pasq8+I/hqSxu00zXtPe/jt3lhWYtt3BCylsDO3oSR
2zQBc1nwXZ654l0zXLm8vY7nS2zbJEyBASckkMpJzwOvbjFVfEvw+07X/ENlr/2u/sNTtV8sT2Mo
jZk54OQf7xGRzgkc8YZo3jnT4/DGk32v61pUdzdxM7PBIfKbaxUlc84BwCTxnPPSkuPiXoMXjay8
OJcRvJPHl5skKjtt8tBxyWz+HHrQBx+oeFL0fF/TRpltqdhpNrposRfwQh9pIfu6sCDuALEHnJzn
Jrrl+GejWek6TZ6fLd2U+kTNNaXcTK0wZvv7tylWDcZBGOB0HFbMXjDw9PfT2UesWcl1CHLxJICw
2DLY9SB1AyRUdh458LatdW9rYa7ZXFxcMViiSQFmIGSMdelAHPXfwj0K68LReHkur+C1S6N3LIjo
ZJ5iMbnLKegPQACtrxR4JsfFtpp0N/d3sc2nyrNDdQOEk3ADJPy7RnAPAGCOMVQ8eav4x0q3nufD
ljYNaWcBubme9c5cDcSsagjkBckkjqAK2fBevSeJ/B+m6zPb/Z5bqIs8XOAQxUkZ5wcZHsRQBmL8
OdI/tGG6nudQuY4rpLtLeeYPGJlUKr8ruzgDPzYJAyDXa0UUAFFFFABWT4l/5FbWP+vKb/0Bq1qy
fEv/ACK2sf8AXlN/6A1AD9CwfD+nYcuPsseHJBz8o544rTrM0JZE8PaasrbpBaRBm9TtGTWnQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAJzk9MVm+If+Rb1T/r0m/9AatOszxD/wAi3qn/AF6Tf+gNQA/Qv+QB
pv8A16Rf+giijQv+QBpv/XpF/wCgiigDQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKKACiiigAooooA5L4mf8k117/r2P8xXW1yXxM/5Jrr3/AF7H+YrraAPNvG2mwa5r
smna94fvtQ0X7LHJBfWcBaS1nLOGUbfmIKqhOAwBAyORjzybwL4q07wTpclva313BpuuNeQaew2z
m3+UKxUZ2tlWJUZI3k464+jKgklSKNnkYKigksxwAB1JPYUAeH6voOoLbaNcaH4O1S3E2ryXZnlk
8y8ttwj3PsZtiMxVsbtygKCcFuMBfDviCL4KT+HW8O6t/aA1YSqgtiwdcckYycDb1IAORjPOPoXT
NW0/V4Xm02/tryJW2NJbTLIqtgHBKkgHBBx71FHrukTXF1bxarZS3FqGaeJLhS0IU4YsAcqAeuel
AHl/jjwhPY2nhfW/CuhBk0+8ju7mwt4NskpxHtJXGcqFK4xkbs9jWX4g0JJrrwlLpPgzVLTTo9Ya
/vIJLZpWCFotzMoLbdwU/J6KOBkCvbbK+tdRs47yzuobi2l5SWFwyvzjgjg8gikiv7We7ntILqCS
5t9vnwpIpeLcMruUHK5HIz1oA85+Emm3mm3Pin7Zp13ZR3OpNPAJ7dog8ZJwV3Afl1HFYXivwdr7
az43W20qe+j8QQWws5omUhWV13K5Y/LjBPpgDBHb3GigDx6DQNb034l+D55LC7ubXS9ISwurxF+Q
SFGGR3YAsuT7+xrrfGsd1PPp1m+iS6xo06ypqVuiqSF+XY4zg7lOSApB6kcgV2lZOm69pGr3FxDp
2pW11NbHE8cMgZozkjDAcjkHr6UAeKP4Pm8OaH46vNNhv7Lw1c6ZiG2vwVdpcgkhT8wCjcoLYJ3d
8Zp3hvQNS8Qy+AbjTrG5s4NM0+QXN9JEFXLA7Qpz82Tk8dN3ODmvaNc0Wz8QaTNpmoLK9pOAJFjk
aMsAc4JUg445Hel0TRbTw/pMOmWCyraQgiNZJWkKjPQFiTj0HagDw/wf4G1tLWTQ77Q9Rt9Us2ul
ttTe5ZbSFZYipZcH5mLYHyg8HJwRWp4O0bULTwv/AGdqXg29TV9KtLy3iveimOQMwVAD+8ZmbGMY
Aydw6H3KigD5ztvDXia38NeELGPwzqEd7ateJNdwqBNCJC2FG5tiqytyzA47YI5ji8M+I3+F2gaS
fD2pJdWmsm6lRoP+WQDZbGc/xAAEAnBxmvpCmFgMZIGTgZ70AeB6rod7qPiPxw91oGsvp+pm3EEs
Vq6sQkihnUEclcFgpxuA7ZzVK68KeMf+EKic2tzfmw1/7UimAxXF1EqKiylWG7Py4+YE4JJyADX0
ZRQB4PfeE9S+0aJ4i0Xw5qiQW2tm/nsLyRWuZdwjLSbScKdyMAC2eQcAV0vww0rVtP8AFXjC+1DR
7myg1W8FzbtMUzgs7bTtY84cdMjg816nRQB4v418LXfib4u6XdzaPqE2hxWbWlzPGhXax83BU5yc
F1O4cflWXp/g7xbpPhjxV4HTTt0N0DJY6pEiqJsFWMbnOfmUFQW+6SRkgjHvlFAHzhf6IY/hpqd9
qnhnVLG6tdMisZ55rkr5rLLEI1jjOQUBUMxIGOi56iLQdR0q9k8RjfqMniHUtBbT7SzXTzErqsCq
NqhmJYhA3YABu2K+gdW0my17TnsNRgE9rIVZk3MpyCGUgqQQQQDkGqNh4X0+yvkv/wDSri7jVkim
vLmSdog2MhdzHbnHJHJ9cUAeEXHhHWJ/DeiwxaNrVhq+nafJEksdqzRzM0spaFwOFDKwO7lSGYNX
aDRvE1r8U9J1ObSZX+0aJHZTXNqF8m3mxh2JPAVeSB34AzXslFAHg3w98L3+jXlpa634a1Z73R7q
a4hvBKfsyxso3FQpy7sVACgHORnGDW18FfCo0zRZ5dY0FrbVobx5Yp7q12yBGUKNrEezAgdM+9ev
0UAeWfFXVNekt4tB0nw7qmo2VxhtQltUZd8Wf9Ur7WwTj5jg4HHfjr/Bl1eXnhW0kvdIGkHDJHp+
Dm3iUlUU5AydoB6DgjiukooAKKKKACiiigArI8TAN4W1gEAg2UwIP+41a9ZPiX/kVtY/68pv/QGo
Al0UMNC08MQW+zRZI9dorRqho2f7D0/JBP2aPOP90VfoAKKKQkAEk4AoAWiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKK
ACszxD/yLeqf9ek3/oDVp1meIf8AkW9U/wCvSb/0BqAH6F/yANN/69Iv/QRRRoX/ACANN/69Iv8A
0EUUAaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH
JfEvn4ba6CcD7MefxFdbXJfEz/kmuvf9ex/mK62gDyz4keOtZ8L6mttYvbQQtp73McjIJpZZlY/I
UByqbRktjA55GDUdt8R9X1m98HaTYR2tpe63aNd3MzxtIsSqrHCrkfeKN1PAI+tdH4i+G2h+J9d/
tbUJb9Z2tDaMsE5jVkOeuBn+I8Zwe4NVm+FuhfYtHt4bzU4J9I3fZruK4CzBSclSduNvPQAY/E5A
PMPBvi688G/DbVLm1jge/uvEbWkZlB8pWaNSWIBzgBTxnuK0bY6hZfE74iy3ktpdXkOh72LQkRyq
sURAZN3dQA2DjJOOOK7mP4SeG08M3uhNJfS2l1cC6Lyz5eOUDG9TjAOODkHPeprX4X6XbXmqXr6p
q9xe6lbG1ubie5VmaMqFI+7joB1BxgYxQB5gmt63caH8NbXTJLDTbPUbuQrbQQMY1liuMKzZbcy/
Mp25HzAkk5GOgufG1x4S17x7e3VhYT3tklmqzwQtEbh3GF8zLNwobtgkD6Y6l/hNoZ0jR9M+2ans
0id5rOZJ1SWMOwZl3Ko4JGc/eHY1al+Gmi3N5rc95cXtwmsxpHdQSOuzCY2FcKGBXAwc9uc0Ac43
jzxFBdaxo96LL7fFoX9rWlxBEVCsEDNGyszZGcjORwOnIrN8IfEHxXe6/wCE4dVvNPms9cimYpHB
5bJsLgfNnkkqOgx2967W2+Gukwx33n3uoXVxeWK6c1xM6CSO3AC7E2qAMgDJIJPrUGn/AAq0PTbz
SLiC81QtpLs9orzqVjDMWZcbeQSTnvz1oA46z+KPiM+ONK066Ng0d5qUlnNbQKJEiQFApWZWIZ/m
JYZ4wMgbgBs/C3A+InxJGR/yEUOB/vTVoRfBvwtbPA8R1MSwXbXcTLeMpRzjIXGAvReRhjtX5uK3
tD8HWPh3XdV1e1ubxrjU233KzOpQsCSGACjBG5u+PmNAHHeIPE3jb/hZ134Y8PT6d5bWQuYzeQnE
XAzyvJJYYGQfve1Uz4/8Y3etapp+m2VvdXeiLbx3FtDDlbpycTHczAooIO3g+9d8fBtkfGw8Wm7v
jfiPyBGXXyhHjG3btzjPPXOapal8ONB1DxJNrr/bbe5uU8u7jtrloo7lcAFZAvVSAMjIBxzmgDh9
T8feM4tY8XQWVxp4t9BRbhVltCXdCQdhIbAwCcnvtGMZq1J8TtY1y9s7TRPs1m39htqs7zQmQNIF
J8oDIwuRy3J9Pdlp8P77V/Hvip9UttSsdG1RVSJ4JY1WVVK/KwyxAO0EcA44yMkV2epfDvRb6S1e
A3Vi9tYnTkazkClrYqV8ttwORgnB6g85oA4mb4oeIr2DwbPolvYGTX/MglguUfbHLG4VmDBgdp3Z
xgnA7k1W1K78cn4ieDdK1nU9Oju3M8yLbwM0KsBIoZl3KXO3pyuM+uc95N8NtGebQnt5Lu1j0Mf6
DHA6gKSQzFtyksWIGcn+Zq7rvgnTPEGv6drF1LeRXen5ETW0xj3AnJDYGcHkHBGQSKAOM8JfEPWd
a+IM+haq1tZNHJMPsLQFWIX7hSQsd2RkngdAVyCQPXK4zSPh7pekavYah9qvbySwSRLJbpkbyA+d
wDKoZhycBiQuTjGa7OgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsnxL/AMitrH/X
lN/6A1a1ZHiY48K6weTiym6f7jUAWtI/5Ath/wBe8f8A6CKu1m6IMaDp4wRi2jGDj+6PTitKgAoo
ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiii
gAooooAKKKKACiiigAooooAKzPEP/It6p/16Tf8AoDVp1meIf+Rb1T/r0m/9AagB+hf8gDTf+vSL
/wBBFFGhf8gDTf8Ar0i/9BFFAGhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACE
ZGDS0UUAFFFFADSARyAe9OoooAKKKKAOS+Jn/JNde/69j/MV1tZPiDRofEWh3mk3EkkUV1GY2ePG
5fcZBFZP/CK6/wD9D3q//gLa/wDxqgDrKK5P/hFdf/6HvV//AAFtf/jVH/CK6/8A9D3q/wD4C2v/
AMaoA6yiuS/4RbxBjnx3qx/7dLX/AONUp8MeICSR451UA9vslrx9P3VAHWUVyR8NeIjJuHjjUgCe
V+yWuPw/d8frTx4d8QqCF8aX5OOr2dsfT0Qeh/OgDqqK5VPD3iHjf4xvDhQDtsbcZPc/dP4envQ3
h3W5gBN4x1QYA/1FvbJk556xt/8AW96AOqorlT4Z1djx411kc5/1Np6cf8sfXn6ce9IfC+s448b6
0CTk5gtT/wC0eKAOrorlB4Z1veCfGusbQOV8i1yT9fJ+lZOhaX4i1XT5bibxrqqtHeXNthLa1AIi
neIHmLqQgP1NAHoNFcn/AMItr23H/Cdavn1+zWv/AMao/wCEV1//AKHvV/8AwFtf/jVAHWUVyf8A
wiuv/wDQ96v/AOAtr/8AGqP+EV1//oe9X/8AAW1/+NUAdZRXJjwtr4IP/Cd6ufY2tr/8apyeGtfV
s/8ACcaow9GtLX/41QB1AGAAST7nvTq5b+wfEPmA/wDCY3uATkfYrbkdv4OvTn68ejR4e15wTN4x
1ANkY8m1tlGMDIIMbdTnvxnvQB1dFcq3hjW8YXxvrIOOpt7U/wDtGm/8Irr/AP0Per/+Atr/APGq
AOsorkv+EW8QYOPHmrZ/69LX/wCNUf8ACLeIP+h71b/wEtf/AI1QB1tFcn/wiuv/APQ96v8A+Atr
/wDGqP8AhFdf/wCh71f/AMBbX/41QB1lFcl/wi3iDn/ivNW/8BLX/wCNUf8ACLeIMc+O9WP/AG6W
v/xqgDraK5P/AIRbX/8Aoe9X/wDAW1/+NU0eF/EPOfHeq47Ys7UY/wDIVAHXUVyJ8L+Ie3jvVhx3
tLU8/wDfqj/hDtRb57jxp4gaQ/eMZt41PGOFEWBQB11Fch/whN7k/wDFa+JevH76H/41SN4L1Asd
vjbxGMtk5eA8eg/dcd6AOwrJ8S/8itrH/XlN/wCgNWOvhPU1dQfG2vlQehFsSeMdfJ+p/wDrjNRX
ng3Ur+CWCXxprbQyo0brsthuVhgjiIdieffjFAHSaNu/sLT92N32aPOOmdoq/Ve2hS1tYrdCSsSK
ik9SAMDP5VYoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooo
AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs3xBj/hHNTycD7JLnH+4a0qo6pALnSb2AsVEs
DoSO2VIzQA3Qv+QBpv8A16Rf+giijQv+QBpv/XpF/wCgiigDQooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5
3wb/AMge7/7C2o/+lk1dFXO+Df8AkD3f/YW1H/0smoA6KiiigAooooAKKKKACiiigAooooAKKKKA
CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK
KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKr3f/AB5z/wDX
Nv5GrFV7v/jzn/65t/I0AV9C/wCQBpv/AF6Rf+giijQv+QBpv/XpF/6CKKANCiiigAooooAKKKKA
CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK
KKKACiiigArnfBv/ACB7v/sLaj/6WTV0Vc74N/5A93/2FtR/9LJqAOiooooAKKKKACiiigAooooA
KKKKACiiigAooooAKKKKACiikJA6mgBaKKKACiiigAooooAKKKKACkOccAGlooAKKKKACiiigAoo
ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiii
gAooooAKr3f/AB5z/wDXNv5GrFV7v/jzn/65t/I0AV9C/wCQBpv/AF6Rf+giijQv+QBpv/XpF/6C
KKANCiiigAooooAjRty7hnBGeQQfyNSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXO+Df8AkD3f/YW1H/0smroq53wYQdGu
iCCDquo4I/6/JqAOiooooAKKKKACmk4BIBPsO9OooAKKKKACiiigAooooAKKKKACiiigDnPG0stv
4F1+eGR4po9OnZJEJDKwjYggjkEetZtp4B0iezgle71ss8asx/tm56kA/wB+tH4gf8k68Sf9gy4/
9FtW1p3/ACDbX/rin/oIoA5z/hXujf8AP1rn/g5uv/jlMPw58NOMzW99M/eSXUrlmP1Jf8K574n+
KNf8MaloI0rUEih1G4+zSRyW6vs5UbgTz/F0PpVnT/Guq6Z8Sl8F6+YLkXUXnWN9DH5TMME7XXJG
flYZGOQOOeADb/4Vt4X/AOfG4/8ABhcf/F0n/CtfC2QfsNx/4MLj/wCLq1p/jXw5quotYWOqwzXK
78KAwV9v3trEbWxnnaTUVt4+8MXyzmz1aOUQQtcPsjc5jVtrMvy/MoIIJXOKAI/+FbeF/wDnxuP/
AAYXH/xdJ/wrfwsQVFlcjPBxqFx/8cqtD8VPBM8iqniS1BYFhvDqMLnOSygA8Hg8njHUVqQ+MfDt
34el16HV7ZtLhYrJcFiqoRj5SCMhuRgYycjHUUAUR8NPCwfd9iuj14OoXGO3+37frSy/Drw06BDb
XowAARqVznA7ff8Aw/GrieNPDraPc6qNUiFnbyeXK7gqUfjClSA245GBjJrmPBPjK/8AEXjnxDpM
tzHcWFgFa3k+zmKQ7jyGBwQRyMYB45oA3l+Hfh1JBIsN+rLwMancjj0/1nTPNSDwHoS52nU15BGN
WuhjjHH7yjWfHnhrw9qB0/V9WS0utgkCSRvypzgghcHoRweox1qceMvDx0GDXRqsH9nTt5cUoyd7
ZI2hcbi2QeMZ46UAU2+H2gnI36sAV2HGrXXI6c/vP84p5+H2ikEfada5Of8AkM3XH/kSqfiH4kaF
o3hKbX4bpbpC7QwRxg5aYD7jDgqR1IbBA98Ct+x12yuvDy6yspe18lpXdEZsbc7sADJwQRwO1AGX
/wAK90bj/Sdb6Y/5DN1/8cpp+HHhlzl7O5Zu7NqFwST6k7+TUWn/ABO8HaneRWdrrtvJLKjyLlWV
QqKWYszKAuApPOOBmqOr+PrDUvCOu3nhnVVN9p1sbkeZAwyo5BCuBuU4I3DjmgDU/wCFbeF/+fG4
/wDBhcf/ABdH/CtvC/8Az43H/gwuP/i6zNH+Imn2vgnQ9T8R6gkV5fwGUrFCzEhclm2qCQoA5OMC
teLxz4cudVGlQamJ71ovOWKKGRiybd+5SFIIK8gg88YoAj/4Vt4X/wCfG4/8GFx/8XR/wrbwv/z4
3H/gwuP/AIuln+Ifhi20631CTU821yjSwlYJCzIpwz7Qu4KP7xGPei9+IXhbTbaxurrWYo7a/Qvb
TbHKSAHBwQpAIPUHBHegBp+GvhY/8uNwPpqFx/8AF0v/AArbwv8A8+Nx/wCDC4/+LqlqPxO8NweD
rvxFZXovbeGTyVWNWDPMRlUIIBXPqRjHr0re8Ma5D4k8P2eqQHiaNS6hWAV8AsBuAJAJIz3oAzv+
FbeF/wDnxuP/AAYXH/xdIfhr4WOP9BuOP+ohcf8AxdddRQByX/CtvC//AD43H/gwuP8A4uk/4Vt4
XwcWVyCRjI1C4/8Ai666igDkD8N/DLEE2l3kAjP9o3HOev8AH7msjVvB2g+H9T8P3ej6ellMdWiV
zEzfOpST5SCcYzg/UV6NXKeL3C3XhkFM7taiAOM4/dynPt0/WgDq6KKKACiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACq93/x5z/8AXNv5GrFV7v8A485/+ubfyNAFfQv+QBpv/XpF
/wCgiijQv+QBpv8A16Rf+giigDQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKKKQnAzQAtFIDkZpaACiiigAooooAKKKKACiiigBCcDoTXPeDM/2LdZA
B/tbUc4/6/Jq6Kuc8F/8gO5+Uj/ia6jweo/0yagDo6KKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigDm/iB/wAk68Sf9gy4/wDRbVtad/yDbX/rin/oIrF+IH/JOvEn/YMuP/RbVtad/wAg21/6
4p/6CKAPLfi9pWrazq3hpNM0i9u10+7+0zyRRgoFLLwCTyeDxST+ENa8Y/ElvE9zbSaPY2dm1tZi
Zl86VirgOVUnaA0jHk5+UccnHo2seINJ8P26TavqENokjbEMjcu3ooHJP0FW9O1Gz1awhvrC4Se2
mXdHIhyGFAHhXhTwDrcmjnRdQ8PXNtqVil5Hb6nLesIUWWNl+RVYgsWYdBjGSTkAVY8F+EtX07TI
hqXhjUU1LTLS6iFw9yHjdJA+2OKMEgsWfnooAJzk17zRQB83aR4V8QWlt4ESfw1qGdH1C4uL79wD
8rSRspHPzHCn8hSQ+BPFV38LNT0tNKuYL9NYGoC3kAXz4jGVwp3YJB5x7DuRX0lRQB4JrHg3V7vT
I9a07w7fRSJqVve3VleXQluLpkVtzAFiMAttA+8wJOOmej8DWert8T/Eut3eg6hY2OpJGYHuVVSM
AcMAxOT7Zx0OK9YooA8l8Y6TqF18W9C1WPR7y706ys5Y55Uh3ruZZNoA78sv0/CuR0rwf4lsvCHh
aSbSb1X0XXPtd1aKm6RoiyNvRQfmxhhgc8/WvoiigD591Twb4juvA/jK5i0u5U6tq63lpYbAJREH
Zi23qCQw+XG75elewW7XV14JBewngumsmUWrkeYG2kBTzgE8cZ4zjNdFWY+tabFrcWjyXsS6jNEZ
o7Yt8zICQWA9OD+R9DQB5N4S+H9+fg/qmkXOjJZ67KZhFJOih23BSAHGSAQoU9On41RsfDWrL4Jv
Ul8JX0OtRaM+lGV7ppDNlgFWJN5UIBlmJAAIG3Oa96ooA+fT4P1+0vfC+oXHhu9vbGHSTpt9ZWs5
hmVsyBuVZflbcDkHBGQccVt698OdT87whe6Bbtpd3bKbG7EM5lNtA4Yk7mOW2hnGfVhjgCvU9W1i
w0Kwkv8AU7gW9pGQHmYEqmTgZwDjkgfiKtWd1DqFlBe20qy29xGssUi9GVhkEfUEUAeRfEPwrrN1
rul2nh/w+xs4dKltFvLRkWQAq6rCWYgKgyueMkMwB61gReHPEEfhn4f2M3hu/Mmk6i9xdqFDARGY
NnAbuCeDzx6EZ+hqxNc8TaR4cgjm1e9W0hkO1ZHRipPpkAgH2NAHjSeFPENz4L+INiuh3cVxqmoR
3VnFIiqZEE4Ygc4yFGcV7B4PF2nhDSI76yezuYrVImgdgzLtAUE44BIAOO2cVBb+OfDN3DdzW+rw
OtmgknUBt8acfMVxu28jJxgd6sWPi7Q9S0m41SzvxPZW3+tnSJyo9cfLzjvjOO9AG/RXJTfETwlB
FbSy6zEkd0N0DNG4Eozj5Tt559K1dK8RaVrZkGm39vcPEcSIjfOh/wBpTgr36igDYooooAK5bxe2
248NDZndrUIzj7v7uQ5/TH411Ncn41OLzwoMddciH/kKWgDrKKKKACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKKKKACq93/x5z/8AXNv5GrFV7v8A485/+ubfyNAFfQv+QBpv/XpF/wCg
iijQv+QBpv8A16Rf+giigDQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA
KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopDnBx1oAWud8G/8ge7/AOwtqP8A6WTV
0Vc74N/5A93/ANhbUf8A0smoA6KiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5v4gf8A
JOvEn/YMuP8A0W1bVgc6dak9TCv8hWL8QP8AknXiT/sGXH/otq2dPJOnWpJyTCvP4CgDyT4sWctz
8QvAUYvZESe6kiVfLRhEd0W5gGU7iQQCGyPlHHJzHBdeNb3x1r3hPw7rlnptlpYjkgD2UXyqxU7V
CrjGGPOOwHGSR6Dr3gvR/Eeq2Wo6h9sN1ZkNatFcvGIWzksoU4BJC5P+yv4zad4Q0rSfEN5rtrFO
uoXqkXEj3DuJBkEZDEgYwAMdAKAPJ7r4l+JIdMv/ABWt0FsbfXRpy6YYV2tCFLElsbg/TkNjOeKZ
4n8aeM7LWvGK2OvJDa6H5MkaPZxM7h3VQu7aMAbjyQTwB3Jr01vh54cl1N71rNysl0Lx7YSsIGnA
wJTGDgtyfbnOKgvfhh4b1K+1O6uo71pdSP8ApgF24WUBgyggHGAQMDsAKAOW8GeLvEt78QLHS9Z1
KK6ttQ0aPUFijtliETMAwAP3jgEg5PPpV34r+Ldd8LXOnvYyTQaa0Un2meCBJWSQ4EZYMDhc57qT
82DkCui074c6Do+sWeq2rXwu7SIQRO92zARAbVjIJ5UDgCruu+DdM8Q3puruS8jka2azlFvcNGss
LEkowHUHJ/OgDz1/GnifxD4gTQfD+q28N3BosV8sjQqVvZ3WNiMsvyptYkYCnPX2XU9b8fn4hWvh
fTdXsoJ59KW5lE1urRwy7TuCkLuI3LgZzgN0OK7LVfht4Y1S5sLmSzlt5rGIW8MltO8LeWowFJUg
kAZGeuCeatReBdGg8T22vQLcRXltAttCqTERrCq7Qm30x+tAHnknjHx9deJtS0TTHgudS0a3g8yK
NIVjun+XzXZpGUqvzHG32yBSt8QPF+reLNbi0O3V4dJuokaybyQjQ/MJWkkZgVOVBBU4Hf37rVPh
14e1fX21u7tZhdyp5c/kztGs6jAxIoI3AgAEdwADmku/hv4ZvPEL6xJYyLPKFE8cczJFNjGA6KQG
HAyDwcDIPNAHmGu+OfHNje+MXtNeh+y6DcRKqSWkRZ1kk2qMhccZ5PfHaty51a+vPi/4ejFysa6p
ohnSVLSIzW26KQ4SRlLY3Luw2eSRjBxXUXHwr8O3h1Qyyaiy6s4lvALo4mIbcM8dATkYq2Ph3ow1
iy1Qy3/2uytRZ27i6YFYgpXaCMHox565Oc0AeT+GfiH4ynu/CN1e66Lm31XUpLKa3a2jUbVMQyWV
c5PmnpjG0deavaz438aza9rFjp+o3FvqcGsJZ22nQ2kci/ZiHPmnKFj0Q7s4w3TkY9Bg+E3hC2S0
WKxuALKcz24+2zYikJUllG7AJ2r+Qrhr/wCHPiddW12awl1m1ur3UJbi0msNSSO0VXbIaRWYSbgO
u0Hpx0FAHbfFJJYvhLrcckjTOluitK4ALkOoJIAABPXgYrhvD+q+LNMvPCHh+HXzLaa3oqtATaRh
rJliJUrx8wXaoO7ORnocEeu3Wgw6t4WGi62TeLJAkdywJXzWGCW45GWGax4fBdl4eWbUdCs/tOr2
1m1vp4vrh5FhUAlYlLH5Vyccc4OMgUAcZ4E8WeJvEl8mh3+qXEOsadqEx1TZBFs+zqAoUfJgEyfK
MHONx/u40v2gf+SZt/1+w/yauj8H6Lc2suoa5q2n29lq+rPG9xDA25YwkaqBkEgksGbg/wAQ6kEn
R8S+EtI8W28drrMc01sjbhCs7xqzdiQpGSOcfU0AcZ4W8DX914ti8XaxLZpG2mx2sNnbM0gZTEqk
yMyrnIzwAeo5454/w7Df+FvFfiT4aIkwh1aQNYTLz5ULcO+fUQ5/4EmO9e56fYpp2nQ2ULStDENq
GWRnYL2BLZJx057CoG0LTm8Qprht86glubVZsniMtuxjpnPfryaAPKfjZbW1kPBFtbosUEF75UcS
LgKq+WAAe2AAP/1Uuuq1p+0xoZ0xAstzZg3oj/iGJQS2P9lUPPotegeJvAej+Lry2udTa8ZrU5hW
O4ZFQ5BJAHGTgc+wq5pHhPSNE1G61K2tnfUbrAmvLiVppWHHy7mJIXgcDA4HHAoA6CiiigArkvGp
IvfCeDjOuxA+/wC6lrra5LxqP9M8J84xrsX4/upaAOtooooAKKKKACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKr3f/HnP/wBc2/kasVXu/wDjzn/65t/I0AV9C/5AGm/9ekX/AKCKKNC/
5AGm/wDXpF/6CKKANCkAwOTmlooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA
KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vwYwbRblhnDapqJGQQf+PuXsa6
Suc8JfLaapEPuJq15t9t0rMf/HmagDo6KKKACiiigApDwDxn2paKACiiigAooooAKKKKACiiigAo
oooA5zx//wAk78Sf9gy4/wDRbVtWP/Hhbdv3S/yFZnjKJZ/BGvRuMq2nXAI/7ZtVjQ5Xm0DTppv9
Y9rEz4AA3FQTwOBzQBna34y0Tw3eQ2eo3brdzxtLHbwwvLIUUEs21FJCgKTk+h9DWT/wtnweLCC/
fULiO0uJGjinezmVGZcZAJXHGf0Poa4v4pym3+IumPaWl9Lff2VMkr2EC3EhidmQAxnG0Dc2Gz1Y
Dmsv+yz4k8JeGdP8J6Bqk1rouqsb9L5oo5FdSrMpDMASdx4GAMYOKAPT4PiX4UurKC6t9QlnE8zw
wxRW0rSyMg3NhAu4gAgk4xU8nxA8NJFpM41HzINXk8qzljhdld8hSpIX5TkgYbB6+lYfiPwtqEPx
H0LxVpenfbbWygmgntIGSNgzCQhwGKqcs/POeh5rjI/ht4n0rwP4XENil3qGm6qb+eyW4VSqkqQo
ZjtJ+UZwercZxQB6SPiP4Z/s3UNQN5OtrpswgvGa1lDQuxKgMu3I5GOnBwO9WtC8f+GvEmoNYaVq
Pm3ITzRG8Lxl0/vLuUbh9K8e1fQ9e0fwB8RrrWdHewXVLqG7hJmjkGGuQSpKMTkbh2A611PhTw/q
ur+LPCHiRtPlsdN0zQY4N8skZa4cxsoChWJ24cMC2PoDQB32veMtA8K3FtDrV/8AZGuQfKZonZWw
QD8wUgYyOp71nL8TfCcmm299HqplinMgjWOCRpCIxlyUC7gFHJJGMc1ifEvw7q2veIfCM9jpEt/a
adefaLsK8SjZujJUB2XJIU8dPes/x54K1GTxxomuaVorX+mw27Wl1ZWdz9lcBmfJBDLwfMOecHBz
wTQB2eo/EPwtpscMlxqgcS24u18iJ5SIScCQ7VO1cnGTiptR8YaHb2NjN/af/IUQmyNrC00sg253
KiqxIUHJyMDv6V5P4h8BeJXNva6X4YitrMaTLCRZ3i7lZmdhE8kjFnVcjgYDE4yF4FvTfC/ifRdR
8Ca4dDubgaVZyWdzZRzR+YjMJFD8ttwd4PXgLzigBdL+JOsX3w61TU7jX7Ozuk1UWtpeTWbGMxgK
xDBVbBZd2Mj246jvdR+J/hDSLqW01DV/JuoVVnQ20ucEAgj5eQQQeCeK8tTwP4sPwq1jRz4enS/v
tVW7SFJ4Sojwued/GCuMYz098aureFfE154r17UovDdwYL3w+2mw5ngB84xoMkeZwoIIz7UAejX3
j/w5YxWEr3rTG+hae1S3haVpI1UszBVBIAAOc46H0q74f8VaV4p0xtR0mSaa1WQp5jW7xhiBzt3A
bvTjPPFeGXtvq2gN4NtTpmqRatZ6XcxTJYwi4lCszL9wHAGGJ3Z6kelepfCm50h/CJ07SbK/s0sJ
2gnhv1CzCU4Zi2OOdw4wMdMUAYz/ABUTVtO8VLYyT6Z/Zw2Wl7Jp8soQjAZpAFIX5jgAjIHJU4Iq
QfFKOyu/CulMZdQnvoFlu7yGykw6mMkGJAMkswBOAQozkA8LixeE/F1lpfxA01NEWVNXmkktJVuY
8ybnwAFLDACsWJYjGAADUlp4O8UWes+AtSg0RGOk2TWl3FJdRgRN8y7yQTkfNu+XJ7YFAGp4O8cX
VvN4zbxVrfnWGh6h9minlhRGVQ7qMiNRuJ2r269K7vQ/EumeIY520yWRmtn8qaKWJonibGQGVgCM
jpxXi+ofDvxXqmm+MkGmyWkl7q66laq80R85Q0uUJVjhsSBh2yuM5r0r4f6Te2f2++vtAj0i4vFh
WZWvGuZpnQMGdnLMNvI2jr1JJyKALeofETwxpeozWN5qflyQSrBPIsDtFFIwJVWcKVUkKeCex9Kg
1T4oeFtC1O403Ur6eG8thmSM2kp4wDkELhhg5yOMc15j448C+NPEOq+Int9CRbea8ie1NvcRRJMi
7l3uucu5DA7mI2/NjritDxT4W8Vax4u17UIvDlwYr3RRYxlZ4SBKQhPJcfKCGGcZ46c0Ael3/jHQ
7bTbCb+0nH9qxk2P2SBpZZBjO5UCsTgEHlcDuO1cR4K+IepXfgHxRr2qXq3LabK627mJY94CDYCF
A5ZiPxb8KoWfhbxXpl14D1pNAluH0i1ezu7IXMQdc7lDgltuCGz1yMYOOtR+FvBnilbH+xtZ0byL
XUdcGo3snmxsnkqN2whWJ+Z1UY9D9cAHcW/jjTtA02ysvE+qM+sRWkU2oMluzCEttGZPLXag3MAM
47etT658TPDPh3UFstRu5Y5ZIBcQlYGdZkIyCrKCDnBH1FcX4o8E+ITq/jQ2OnSahF4gt4FgmE8a
iJlZdyuGZTgAEggHgAVbt/BOt2/j/wAIXj2S3GnaPpS2FzcF0w7eW6kqrHcVBYdRng8eoB6ZpGqW
uuaTa6nYuz2t1GJI2ZSpKn1B6GsPxqCb3wngZxrsRPt+6lrp0jWJFRAFVQAFUYAA7AVzHjf5F8Oy
ADcut2oUkZxuLKf/AB1mH40AdbRRRQAUU0gEEEAg9jTqACiiigAooooAKKKKACiiigAooooAKKKK
ACiiigAooooAKr3f/HnP/wBc2/kasU0gMCp6EYoAo6F/yANN/wCvSL/0EUVJpIxpFkPS3jH/AI6K
KALlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABXPeE/8AU6v/ANha6/8AQ66GuD0HxJpelvrFrcPcrKNVuiRH
ZzSDl89VUj9aAO8ornf+E20T/nref+C64/8AiKafG+ggKTPeYbgH+z7jn/xygDpKK5seONCJIE14
SOoGnXHH/jlIfHGgAEm4uwB1zp9xx2/uUAdLRXMHx74dVghurkMRkA2Fxkj/AL4pp8f+HFkKm7uA
wwSDYz556fwe4/OgDqaK5Y+P/Da4JvLgA4wTYz85xj+D3H5imf8ACw/DnSOa+mx1MOmXLhfrtjOK
AOsorlU+IOgOAR/aY/3tJuh3x/zzp6+OdCY5DagOcc6Zcj0/6Z+/86AOnorm/wDhONDzgS3hOcHG
nXHH/jlA8caEw4mvD34064/+IoA6SiuZHjrQG24nuzuGVxp9x8w9vk5p3/Cc6BuC/aLvJ7f2fcZ/
9AoA6SiuZPjnQFPNxdjtzp9x/wDEexrM1j4haTa6DqN1YTzPdw2sssSvYz7Q6qSu75QAMjnJHfmg
DoPFn/Im65/2D7j/ANFtVjQy50DTjJ982sRb67RmvHbH422Hibwxqmm6nZy2Ooy2Eyo0IaWKRvLb
pgbl/HIHc17DogX+wtPCMGUW0W1gchhtHNAFbU/DWkavdR3V7ZhrqNSiTxyNHKqk5xuUhsZ7ZxVd
tR8PeEY7TTmlt9OS5kIgj2kCRywzzjliWHU5Oc1zPxK8TaroF5pkdhfpbRTxTs6wxrLcu6oSm1GV
gVDY3HAwM8ivP/EOval4s8BeA9Svp4l1CbVynnJGANyuVDbemeASOB9KAPomq8syQRNLLIscaAsz
uwCqB1JJ6CvGbjxn40sn8YaFBcR6lqOlNC1tciBEkaNiCyhANrMFOQNp6NweBXPeKfGGqeJPhMl9
HrczxyauLOeNoUjYoYwyq+0AcFSfl4bdzjG0AHvOtaHp/iPTJNL1WH7RaSFS8W9lDFTkZKkHqAcZ
7VJpum22lWFvZWaOlvAu2NGkZ9q+gLEnA7DPA4HFeYeINV8b23xG0/wlpHiCEtdaebgzXVnHhWHm
jgKvT5B64z36Vj+LPHvjLwzJf28+q2Ul3p0dsQlnCskcu7AkabIzGSxGACp54BHIAPeagMiCZYty
h2BKqTyQMZIHtkfmK8p1Pxh4n1zxrceG/D17b6fdWumR3iLLErC5lYIxQswO1dr9gDkdcVX0ubxD
dfHf7HqGqhZLbSUleKONTEoYxNJEoPYt/F97AFAHsnQZrDPinQU0c6w+rWqaeJGi+0vIFQsrFSAT
1OQenXFcj8VvFVvpFjBo1xeyWEeowzNJcojMxRAP3S7QSGZmUEnAC7uc4rB+FlvZa58I4beDTbDV
b+wlnRbe/BEQd23ckqRnaw5APXGRk0AenDxRoR0Y6x/bNkdMB2m689fLDZxjdnrnjHWrOl61pmuW
Yu9Lv7e8gJxvgkDAH0OOh9jXjvwtsNEh8H6vZ+KNLjhbQtQkmvPtZ8yLeUK7tmNp2qMAfN6jqK6X
4SaJ/Ytnqd1JGtlJq1ybyHTSwD21sWIj3L/CTk/gAOowADtNV8NaNrssc2oWKzTRKVSUOyOqk5K7
lIOMjpnFWtO0yz0uzFtp9tHbQhi2xFxlicknuST1J5NeZ+Itb8Zz/Fd/DOga3BZwy6cLpBc2yOqM
ARgHbu5IHXONx4OAKz7rxd46u/FWr6Jo84lvNGt7cMgS3RLlht86SQyEMqnLY2dMrnFAHttFeHX/
AIq8YT+JfGNtY+Ifs9vo2n/boo2tIZCf3Ycx7gvIG4gHnOBz1JktviH4h8TXuhWVncjS2uNHm1C4
ljgVy8i71AUOGAXcgPrgkZ70Ae21DJKibd7BdzBRk4yT0A968MuPiF4t1Lw54K1DTb+G0vNWu3sb
iM2yNHIwkChxkFgMHkAj2xTvEMHjOLxz4O0nV/FPmyzzzSJLa26KkZXIVipXDNtP8QIGTjPJIB7v
RXjmieOfED/Fc+HtXvGgia9nEMTQIIprcI4j2MF3btygkliDgjKkbW9joAKKKKACiiigArkvGxUW
2h5K5Ot2WNwyc+YOnoev611tcl432+ToW4gH+27LGRnJ8zt6d6AOtooooAKKKKACiiigAooooAKK
KKACiiigAooooAKKKKACiiigAopCARggH60tABRRRQBS0v8A5BFl/wBcE/8AQRRRpf8AyCLL/rgn
/oIooAu0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc34RIa31UjP/IVugcjHSQiukrm/CJBt9WwCMatdDnPP
7w0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVR1TT4NW0q80653fZ7uB4JdpwdrKVOD2O
CavUUAcNceEtD8J+AtcttGsIrfOnzh5cZkk/dtyzHk/y9BXVaUd2j2TZzmCM5znPyjv3qr4s/wCR
N1z/ALB9x/6LarWkMG0WxZeFa3jIGc4G0UAY2ueB9D8TanaX2rWrzT2iskbLKyZVuqttIyOTx7ns
cVnD4X+F49GtNJS0uhbW07XMOLqQMkpGNwYNkY6gDjPODzXc0UAcifAGh/ZbqLbd+ddXKXc919qf
z3lQ5Rt+cjGeAMAUl18PPDd9oc+kXVpLLBPetfyu07eY9w3BkLA9SDjHTHauvooA5OHwLo1v4hst
ehS5F5ZQLbW4E7FUiClduD1HzMTnJJJPWqOq/CzwtrF/qF9d2tw0+oFWn23LqpKkEEKDjPH6nGM1
3VFAHEXvww8Nahc6fcyRXkdxYwrBHNDdOkjIOiswO48EjOc4OM1cPgLw+fENnr6WTRXtpEkMYjlZ
UKqAEDLnB24GPoOuBXV0UAV7mCO8tJraUbo5kMbgHBKkYP6GuN/4VloUVlpNtZSajYnSnke1mtrk
q6lzlgSQQwJA4I9umRXdUUAcbqXw70LVdEfSJ1u1tZrj7VcFbhg88p6tIxyWPTg8DAxjAqfwj4D0
PwSt2NGjmU3ZUyNLJvOFztAOOB8xrq6KAOcbwjpbeLh4pIn/ALTEXk7xO23ZjGNucY9vXnrVTVfh
54a1rXhrN5Yub0oEmMcrIs6gABZADhhgAY7gYORxXXUUAeQr8PrzU/iX4lvNV066i0TUoEgjeC7V
NyqEBDBWztO3gY9M45rstQ8A+H9QjsENo9ubGBrW3e2laNlhK7TGSDllIJ656n1OesooA467+Hnh
+6XSFWGe3j0jH2KO3ndBE2Qd2AeWyASTknvV3xB4M0XxNeWV1qto0stmzGJklZDg4yDtIyDjp/ia
6SigDlrPwRpNlrEOpIty8kE009vFJOzRQPKSXKKeFzk8dBk4Gea6miigAooooAKKKKACuS8d/wCq
8P8A/Yds/wD0OutrlPHWPI0DP/Qcs8f990AdXRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAUtL/5BFl/1wT/ANBFFGl/8giy/wCuCf8AoIooAu0UUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQA0EEkAjI606iigAooooAKKYxxjpknAycU+gAoqIBxncQeeM
DGB+dS0AFFFFABRRRQAUUUUAFMY4GeePQZp9FABRRRQAUUUUAFc54ROYdX4I/wCJtddf9+ujrnPC
OfI1br/yFrrr/vmgDo6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8Wf8ibrn/YPuP/
AEW1TaIHXQtPWQhnFtGGIzgnaMkZ5qHxZ/yJuuf9g+4/9FtVjRmV9C091JKm2jILDBI2jqKANGii
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuS8csBBoIIBzrl
mAfT95XW1yXjoZh0Dpxrtn3/ANugDraKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooo
oAKKKKACiiigClpf/IIsv+uCf+giijS/+QRZf9cE/wDQRRQBdooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKKACiiigAooooAKKKaBgYJJ9zQA6iiigAooooAKKjdiiFgpYgfdHU1JQAUUUUAFF
FFABRRRQAUUUUAFFFFABXO+E8eTq2D/zFbrP/fZroq5vwjt8jV8Yx/a1109d5zQB0lFFFABRRRQA
UUUUAFFFFABRRRQAUUUUAFFFFABRRRQBieLDnwZrhwR/xL5+v/XNqt6QyPo1iyfda3jK8EcbRjg8
iq3iz/kTdc/7B9x/6LarWkBhotiGYOwt48sOjHaOaAL9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcn46AMGgZOMa5Z49/nrrK5Lx3/qvD/8A2HbP/wBDoA62
iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApoGBgZ/E06igClpf/IIsv8A
rgn/AKCKKNL/AOQRZf8AXBP/AEEUUAXaKKKACiiigAooooAKKQZxyAKWgAooooAKKKKACiiigAoo
ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiovm3jgYxyc85+n50A
S1znhE5h1fgj/ibXXX/fro657wn/AKnV/wDsLXX/AKHQB0NFFFABRRRQAUUUUAFFFFABRRRQAUUU
UAFFFFABSZGcZ5paKAKWoWcWpabdWE+fJuYWhfBwdrKQcH1wa5pPA7wxQwweKvEkMcSKiql1HgBR
gcGM9vw4FdlRQByX/CGT8n/hLvEmeR/x8xcZP/XOm/8ACEq20yeJ/Ekjj7zf2iV3c9woAHpwB09e
a6+igDkz4FjOP+Kl8TD/ALij80n/AAgif9DL4n/8Gj/4V1tFAHJf8IIn/Qy+J/8AwaP/AIUf8IIn
/Qy+J/8AwaP/AIV1tFAHJf8ACCJ/0Mvif/waP/hR/wAIIn/Qy+J//Bo/+FdbRQByB8CKc/8AFT+J
xkY/5Cjce/Sl/wCEEj4/4qbxPgZ4/tNv8K66igDkD4HPJTxP4nXK7SP7RJ/mpwfcVIPB7BPLHiTx
FgNuB+3ZIP125I9jxXV0UAcyPCThy3/CS6+QR0N2uB/47Ua+B4Fi2DXvEZP986rLn+eP0rqqKAOV
PgmAjH9veIwcEZGqy/n1oHguEEk634iOccHVZeMfj3/ziuqooA5Y+DbchiNc8QAEYGNVl4469fxq
NfA8Q6+I/Ercjrqj/wBK62igDkj4HiZiw8Q+JV6/KNUkx+tL/wAIRFv3f8JD4lx6f2o+P8a6yigD
kv8AhBE/6GXxP/4NH/wo/wCEET/oZfE//g0f/CutooA5L/hBE/6GXxP/AODR/wDCj/hBE/6GXxP/
AODR/wDCutooA5H/AIQWP/oZfE//AINH/wAKWPwDpCXNrcPcatPJazLcRLcanPKgdTlSVZiDg+1d
bRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFLS/8AkEWX/XBP
/QRRRpf/ACCLL/rgn/oIooAu0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAgOexFLRRQAUUUUAFFFFABRRRQAVzXg5AltrCjvq92emOshP9
a6QkAZJAHvXNeGCouvEMe4fLqsm1c9MxxscD6kn6k0AdNRRRQAmecYP1paKKACiiigAooooAKKKK
ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA
KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCl
pf8AyCLL/rgn/oIoqxGixIqIoVVAUAdgOgooAlooooAKKKKACiiigAooooAKKKKACiiigAooooAK
QnAJPQUtFABRRRQAUUUUAFFFFABRSEZHUiloAKKKKACiqGs8aFqGP+faT/0E1yPh/wAAeFJ/DOlv
NoNjNK1pCzyNH8zMY1ySeuT1+vPWgDvaK5Q/Djwex3Hw9YZOekeBz7U3/hWfgw5J8PWfPoGH9aAO
toPSuRb4Y+C2x/xT1pwc8bh/WlPwx8Fkj/inrTj/AHv8aAOsHI6Ypa5L/hWXgv8A6F2z/Jv8aD8M
vBZH/IvWn/j3+NAHW1E8scQBkdUB6biBXJr8L/Ba5C6BbjcMEhnzj67qfH8NPBsQwPD1iwwRiRC4
5x/eJ54HNAHULcQOMrNGw9mBpVljYEq6sBzwwNc23w88HO6sfDGlgjpttlA/IDFPHw98HLnHhnSx
nr/oy/4UAXtf0i08R6Be6TdkeTdxGPcOSjdVYe6tgj3Arxr4LeALqy8S6rqusRnzdMna0hBJIabH
zOPUBSuD33Z7CvUl+Hng9ZC3/CN6duJ3f6gYz9OgHHShvh74PZi3/CN6cCSCQIABkcdBx+HegDqg
cjNAIIBByDXKj4b+DRn/AIp2w5AH+r9Kb/wrLwX/ANC9Z/k3+NAHW005wcAE9s1yn/CsvBf/AELt
n+Tf40h+GXgsgj/hHrTn03D+tAHXUVyQ+GPgsE/8U9ac/wC9/jUTfC3wU+CfD9vkejuO+ezUAdlU
ElxDEQsksaEjIDMBkVybfCzwS4GfD9uMHPyu4757NUkfw08GRgKPDVgwznMke8/mxJxz0oA6kXEL
HAljJ9mFPLqM5YDHXmuUPwz8Fvjd4bsBjP3Y9vX6GlPwy8FMST4dsuf9k/40AdYCCAQcg0tcl/wr
LwX/ANC9Z/k3+NH/AArLwX/0Ltn+Tf40AdbRXmfi3wT4a0XTLO+0zRre2uo9TsgsseQyhriNT37g
kV6ZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUda/5AWof
9e0n/oJqn4Wcy+EdFlIxusIGx3BMa1c1r/kBah/17Sf+gmqfhXP/AAiOjdf+PGHr1/1Y68n+dAHG
/GDxBrPhbQ7DUtG1Z7N5r1LWRGiidCrK7FsspII2jvjHal0/xHPaXuoaxP4muNV8M2Alt55fssLb
JlETBgYVDMuHYcDAK5JxiofjBoOseKNK07TtG0ia9eG8W6eQSxpGFCspX5mBLHcD0xjvWzqPhSOb
wHr2naPYNYTavHJMLSTYoimaNV24UlVBKjOCRlic0AXLPxzoGr6jZaVZ6jOLzUbcz2hFs6749rHe
Cy7eNp69xgjtXkj/ABF8Xr8On1sa0322LxA2n7vs0O1ojErAEbOoIPIx945zxjR8MeF/F9l408I6
jqHhueG10nTjYSOl1C5Y4lAbG4YGXHHPFY7eA/FzfDmfRB4duvtj6/8A2iAZodvleVt67/vZ7frQ
B75quqWmi6fPqN9OlvawDdJK5wqjOPxJJAAHJJArFg+IfhefTL7UP7T8q3sPL+0meGSJk3jKfKyh
juHTAOaqfEjw7f8AjDwDeadY5jvG2SpE5A3lSG2E9AT9cZA5xzXFax4T8SeJ/BG2XwvbabrNrNay
yBZ4y2omJWQgkHCgKwI3MecjsCQD0CT4heHI9N1DUGuplh06RY7xGtpFltyxwpaNlDAH1xUGl/Er
w5rV+LGymuhcPbG5hWW1ePz4wCS0e4DdjB6dcHGcV5z4o8O6nFpHxE8S6jbPYQahFAlvBM6s5VWT
LNtZgMlQAMnqfxu+GfD+tazf+DNfbS2trHR9CVE3TRs10zRELsAb5QQytlsYOQemSAdH4X8b2Vr4
Ng1HV/EX9sST3r20E0NmyPM5PyxrHtBJwRzjHOM9zrt8SfDK29pOt9JL9qMoSKK3dpV8oZk3IBuX
aOoIz6ZrymD4ZeLrbwlowTTUOpaPqkl0LV7lNlzG/lnhg3BBjwQSOGJBNaviHwBqeq6dbmLwiunz
MZriEaZdJ5tnO20KHLMqyK20FiuCvGOh3AHskGp2k+kR6mJQlnJCLgSSfKAhG7Jz045rn9K+IHhz
WJ0gs7mcyPC9zbo1u6tcxKSGaMEZflW4HzHB4p83h+/vfhufD13dAX0uli0knUkKZPL2k8fw568c
jNcL4Y8GeIU1/wAK3uoaWbWPw7YSwSfvY2NzJ86qIwG6EMDltvOfrQBN8OvEnijxp4hu9Vk1d4tL
truaKTTzZ4jaPaPLCyFR8wYksC27AHABrrNR+JfhfStUvNNvby4W7slLTxCymbYvHzEhSNuCDnOM
Gsr4RaBrPhnQ9S0/WNPa1km1B7qNvNRwysqrj5WJBG3v6iuQv0vX+NXjiztdMfULi+0NoUjidFID
RxKCSzABckA4yehx1oA9NvPH3hqytbK5l1Lel5btdQCGF5WaJVLM5VVJVQAckgdD6Gob34leFbDT
9P1C51GT7JqAJtZY7aV1kIOCPlU4YHscH2rzS5+H/jCz0fwzo9npsU6wadcRXdzFOkUkckpc+X5p
ywRSwyF4b5h0NZ2oaXqfh7wl8PdN1bS5Ybu11s4gSZGaUGQMCCDtUktgAntyRQB7Fb+P/Dd3o1/q
qaiFtNPfy7szRvG0LZxtZWAbJPAAHJ4qGb4keF4NKudRm1CWO3tZlgnzazB4XYZUMhXcoOOCRg15
xqvw28Q67p/jW9WyFnc6pfRT2dnLIoZ0jLElirMoZt3GT1B6A1NrHhXxBrPgDVI4PCDWOp6g1qss
f20SyzNESxkdnfAXGFVeWBznjFAHcQfFPwjcOY7TVJLybzkgWKC3dmd3BKhRtG7hTyOOPUjPTaJr
Fpr2kwalYs7W02dhdCpOGKnIPI5U9a8/8V+Dm1zwtotkPDjSKqr9rFs8UVzbssYVWUlgrY5G0kgj
GCMA11XgLS9V0fwTplhrMhbUIkPnHcGK5YsFLDgkAgE85OeT1oA6qiiigAooooA5L4gHb4ctjgHG
qWHB6f8AHzFXW1yPxC/5Fq3/AOwpYf8ApTFXXUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFA
BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFAFHWv+QFqH/XtJ/6Cap+FAR4Q0QZJIsIMktuJ/dr37/Wrmtf8gLUP
+vaT/wBBNUPCAYeDND3NuI0+3y2CNx8teeefzoA3awdd8U6R4YFu+r3T263MnlROIJHUv2UlQQCe
cZxnB9DXMeONd1W38Y+FfDdlczWVtqk0hnuYgu9lQA7FLAgdeT15H4+X+J/Eep+JvhrZ/wBpXBku
7PxMLRbnywpcLGxBIAC5G7nA7CgD6VqtbXMF3bpc28qSwyDckiMGVh6gjqK8T1zxB4ms5vH3hyXX
Lq5h02wS5gvjHGkqFghMZKqBhg7DIwRt4xUdvrOs6F4F8G2Wn645/tGBibdFjNzny12JFldqop5J
Yg8/eoA9h1rxDpnh+K2l1S6+zJczrbRMULZkbOBwDjoeTxWxXgF5418QX/wr8L6w2pxi/m1cWkzG
GFlcAsVYqykKy7VwRjrn0p/ivxV4x03WPGxsvE7RWuhvbSQQtaxMWEzKNu4rnChj6k4FAHt2paZZ
azYS2GoW0dzay4DwyjKtg5GR9QDVJ103wp4fkaKBodOsozIUhDPsUcnavJwBk4HQDivLdZ8XeJtZ
8V6PoOn3v2CW70RLyIqyxia5ZCykkhiUBH3R1wevFVdR8Ra54h1DV9FvtaEEVj4aa6f7Aw8u7mMa
lm3EfMnzEYGB6UAew6Brlj4l0S31fTZGks7jd5bspUnaxU8HkcqayX+IHhyPxMvh43rHUWlWAqsT
FRIQSELAbQ3B4zWX8Fxu+EOhgEgkTjI6j9/JXmGl3l34Xk+KWr2lxLcXenXcSQtcBX3O0zr5rDb9
5QWIxgfM2R0wAfR9FeK2XinxBZavNpjavc3iXPhj+1VkeNGe2uNhYnIXAUkdCCPmUCtX4Xv4v8Q6
XpXibVvE5nspFnRrAWqLvw5UFmXHIKk8DoAO5oA9VrAt/C+kWuvS67FYhNUmBEtz5jbnBAGG5wRw
OMYGBjoK8/8AG3ibxLN8RYvCuiXT2znTmng2skZlnO4qSzghlAXlV6/N6cZ2oeLvFOheKNL+36jN
eWOt6aWtIrNYmUXhTAVHCncN5XBOQA65yAaAPcK4vxO/hC98RaPpniBN+pSNu04MsoG7PJVl+VWB
Azkg9PauJ8ceJvEvhloNPXxE0l1Ho7TutvFGZmuFbLSybk2rDjIAGGOMYJqjqWp3Wt+IfhNqN4+6
7uUd5HVQuWOzJA6A9/SgD3VVCqFGcAY5OafXzne+PvFtv4T1K9j1y4NxaeIP7PRjFD80JVjhhs5O
VHIx1NbnxH8deItC13Wo9P1VQtils8FvaxKyxKxXcbgsvViwChWzgg4HJoA9lmuraC4ggklVZZyV
iQnlioLHA9gCaoaL4k03xD9uXTLhpWsbhrW43Iy7ZF6jkDI9xXlWoC51T44aCtxrF7axy6Ot0PJk
VREzBgyrlSArFRnOSc9emMSPxp4g0rw3rtvBqEjTN4jGnx3bKpeJG3FmyAAWO0cnPU0AfRVFeI6z
4t8RaVpPjyzt9WuTLoFxbNaXbojSFJWwyPlcMADwcZ6c1f8AAmveIpfiDHpWp6xNqFvc6FFqBWSF
E8qRhH02gcfMR+P40Aev0UUUAcl8QRnw3bjj/kKWHU4/5eYq62uR+IX/ACLVv/2FLD/0pirrcc9/
zoAWiiigAooooAKKKKACiiigBOc9RiloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiii
gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBpOASAT7DvT
qKaQCOQD3oAdRRRQAUUUUAFMBBJwQccH2p9FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAUda/5AWof9e0n/oJqj4SEg8G6Gsu0uNPtwxX7pPlrnHtV7Wv+QFqH/Xt
J/6CazvBjiTwPoDhQobTbYhQcgZiXigCfV/D2na8sC6lbeabeTzYZEdo3ifGNyupDKfofT0rPm8C
+GZ9EtdFk0mI6bbSeZFACygPtZdxIOS2GPJOc89awfin42vfCdjpkGnv5NzqF0sTTmAyeTH/ABMo
wVLdMA578Hsad8Q9L0DTo9O8YeIbd9ahTzJ2FpLFvVjlSFKLztZcgD144NAHTWvhHQ7WwvrJbISx
X4IvGnkeV5xjb8zsSxwOBzx2xWb/AMK08Hm3soDocLxWTs0KGRyMsADuy3z5CqMNkYAHSp5viF4X
t5xDLqqqxWJmfynKRiUZj3vt2oWHIDEVHqvxH8KaJqc+n6hqwgu4AGlia3lJAIBBBC4IwQcjPFAE
X/Cr/CA0tNMXRx9jSZrgRi4lGJCAN2Q2cgDA9MnGMnLrr4a+Frya+kubC4kN9t+15vZ8T7W3LuG/
5sEDGemBirOmeO/C+tarFpmn61BcXcsXmxxqG+dcZOCRgkDORnIwcjg1D8Q9e1Xw14QvdV0mO0eW
2UM/2osQFJAyFXqcnuQPr0oAlvvh/wCF9VtrK21DSkuUsY/Kt/MdyUTsu7OSB2BJxT9U8C+GdYeC
S/0a3meCHyI2AK7Y8YC/KRlR2BzjtXJ+J/Hd5pXwh0jWTepa6vqdvbBJzCGVXZQzttwRjAbjB6ji
r/wt1XVda0u7v9Q8U2muqzqsS28Ai8jAOQw2K2TkdRjAyOtAHXaLoWmeH9PFhpVnHZ2wYt5cecbi
ACcnkngc1n6f4J8O6ZJfPa6YobUEZLwPK8gnBOTuDMQxyTyeeT6mqesfEnwloGoXFhquq/Zru2AM
kLwSZIIBBGFw2Qw6Z7+hqaT4heF4LiO3bVV3OsTlhE7JGJQDHvYDam4EYDEUATWXgfw9p1tdQ22n
bUu4BbTFppGdoQMCMMzFlXHG0ECruhaBYeG9OGn6TCYbRWLCLzGYKT1xuJxnrgYGST3rDvPih4Q0
+8ubO51SSO4tHKXEf2SYmLB25bC4C5I56cj1rQ1PxpoOlC1Nxf7/ALTAbmEW8TzFoQMmTCKcKBzu
PFAB4g8E+HfFU1vPrWmR3UsB/duXZWAznBKkZXPY5FaFzoenXU1hLLaRs+nP5lqQMeUdpXgDtg9P
YegrI1P4g+GNIisZ77VoooL+My20wjdklUdSGVSOMjIzkZHrWHJ8XdBuNe0Sx0uSW7hv3kaWVLWU
7EVHwFULuZi6gcAgDdnHBoA3tY8B+GPEOp/2lq+jxXV35Jg3u7AbeewIGRk4bGR2PAqGL4deF4pt
NePTZEOmAfYyt1KPKIbdkYbkk9SckgAHgAVbsPGeg6rqi6dZXzS3LSSIgEEgVzH9/DFQrbehwT1H
qK6WgDh9Q+FXg3Ur24urzRg891L5sjLPKgL9yArAAnknAGak1H4Y+ENUvbq7vdJE9xcxrHK7zSbm
2gANnd97gZbqe55Oe0ooA5k+CPDktxplydLiM+mIiWchZi0QU5XnPODyCc881DH8P/C8NhfWEekp
9mv2VrmN5XYSMCSG5YkMCc5GD711lFAHL/8ACD+HTpFxpclg0lncTefcB55Gad+u6Ry25/xJHA9K
NO8D+HtK1iHVLGwkivoYfIjla5lbbGAFCYZiNoAAAxgdq6iigAooooA5L4hDPhqDkD/iaWH/AKUx
V1tcn8QV3eHIOcY1OxPTP/LzFXWUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA
UUUUAFFFFABRRUYOSRgjBxyOvFAElFFFABRRRQAUUUUAFFFFABRRRQAUmecYP1paKACiiigAoooo
AKKKKACiiigAooooAKKKKACiiigAooooAo61/wAgLUP+vaT/ANBNZ3gzA8DeHwrFh/ZttgnqR5S8
1o61/wAgLUP+vaT/ANBNZ3gkY8A+HB3Gl23T/rktAHJ/FXQtZ13/AIR9dJ0yW8+x6itzOUeNdqjs
NzLknP09SKhj8Oajf/Ge51vUNBZtGl037Kr3DQuN+ATuUMTjG5eh6+hzXqNFAHhut+AvER/4TXSr
TTWuYtevLa4tboSxrHEqybmVwWDLtDAAAHIHFLrHg7xJ/wAJV4guLfSLi8t7nw9/ZcNwJYR5kuxF
3EM4IGVOSefavcaKAPDfDPhDxNZ+KfA97daBcQW2kWUltdP50J2s3mgMAHJI+dSeM9eDXoHxJsb/
AFfwJqOmadp813dXaBEWNkUAhlbLFmAxwema7KigDzmyl8Sad4B0KztPCovbq0SKzvbK6ljQlUjC
s0bFipBIxkn8Kt+CPCa6FrOvatFp39lW+qPCYrDKEwhFOSQhKjczE7VJAA684Hd0UAeYJ4Y1Cb43
XOuXWiCXSJNP+yi4d4iC+F+Yru3EEBl+7+GOaw7/AMB6zF4819z4eh1nR9ZZHSSW+MUVu69GkjDA
sqkngAnA+UjJFe10UAfPzWmpaj4s+J2lWGly3894sUKtHJGoiJztLF2Hy49M429K1/8AhBdf8Oal
p15b2P8AauPDjaS627qPKnwcEh2UFCTjP1JAr0uy8J6Jp2t3Os2lj5WoXWfPlEr/ALzJycqWwfyr
foA8JHw88R2UPw6s30572LRbmS4vnWWLbEJJUfYAzAttCnOAR6E5wOk8TeGtWtfih4X13Q9GiuLC
zhkt3SKRYViLBxk8cD588A5wR1Ir1KigDxrwd4Q1jT/iFHqkOnXWm2D+fJf2tzsaHzGBCtAwZm+b
IJBAKhWUsQQK9loooAKKKKAGkAjkA96dRRQAUUUUAFFFFAHJfEEFvDcGATjVLAnH/XzFXW1yfxBU
t4bgwcY1OxJ/8CYq6ygAooooAKKKKACiiigAorzrQvDdlrepeI7q/kvmnj1iWJGiv5ogIwsbBcK4
GMk9u9bf/CA6F5plH9piQrt3DVbrOO/Pmd6AOqorl38A6E6KhbVAB6atdc/X95TE8AaMhDfadaJ4
66xdc/8AkSgDq6K5Nvh/o7En7XrgySeNZuv/AI5Sf8K+0j/n813/AMHN1/8AF0AdbRXJf8K+0j/n
813/AMHN1/8AF0f8K+0j/n813/wc3X/xdAHW0VyX/CvtI/5/Nd/8HN1/8XR/wr7SP+fzXf8Awc3X
/wAXQB1tFckvgHSUIIvtdBGf+Yzdd+P79SDwJoeQW/tNmH8TardEnv8A89PXn60AdTRXNf8ACDaH
g/8AITyVwT/a11kj/v5TI/AuhKUIGpAoCBjVbrv1/wCWnfrQB1FFcyvgfREGF/tNRwMLq10Bx/20
oPgbRCVIOpqVxgrq10OB2/1nSgDpqK5keBtGDbvN1f6f2vdY6Y/56U1/AmiuSfN1dSRgFdXuhj6f
vKAOoorlE+H+jowb7XrZx2Os3WD/AORKhk8A6aZFxe6yEGSR/a91uJ7YPmcAfQ9e1AHY0Vyh+H+j
nP8Apeuc/wDUZuuP/IlN/wCFfaR/z+a7/wCDm6/+LoA62ivNPGHhi00PwxcajYX2tR3MMsGxn1W4
cfNMinKs5B4JHIr0ugAoqMKFZioALHJPqcY/oKkoAKKKKACiiigAooooAKKKKACiiigAooooAKKK
KACiiigAooooAKKKaP72MEjmgB1FFFABRRRQAU0kAjJ68CnUUAFFFFABRRRQAUUUUAFFFFABRRRQ
AUUUUAFFFFAAelIOeaWigAooooAKKKKACiiigChqkbzaRexRqWkeB1VR1JKkAVx3hnxJPpfhTSdO
uPDPiET2lnDbybbLK7lQKSPm5GQa9AooA5ZvF6qefD/iHBPJGnseOeeD7fXkU7/hMIgVH9heIMt0
/wCJc/6+n4109FAHLv4yiRNx0LxCRgn5dNkJ/IU0+NoAm/8AsHxHjp/yCpc/ljNdVRQByf8AwnVt
j/kA+JO3/MJm7/hR/wAJ9bf9ADxN/wCCaf8A+JrrKKAORHj21IBGg+JyD/1Bpv8A4mk/4TlHx5Ph
nxPKR1H9mNHj/vsqD+Ga6+igDk/+E4f/AKFLxP8A+AS//F0f8Jw//QpeJ/8AwCX/AOLrrKKAOSHj
VyzD/hFfEvAJBNkvPsPmpqeOoJWkW38P69M0T+XMEsuY3wG2nLDnDA8Z6119c74f/wCRg8Wf9hOL
/wBI7egCP/hL0BAOha+CRn/kHsce1KfF8YcL/Yev5P8A1Dnx+fSulooA5n/hMY9rMNC8QHb2/s58
n6etQnxtbrtJ0LxF83TGkzH068cde/v6GusooA5M+OrYDnQPEv4aPMf/AGWj/hPrb/oAeJv/AATT
/wDxNdZRQByf/CfW3/QA8Tf+Caf/AOJpF8bRyDdF4e8RuQDw2mOhz6fNjr/SutooA5n/AIS9SCTo
GvrjPWwY/wAjTD4yjWUK2g+IMNnDDTnI49cdPxrqaKAOUPjaBY1c6H4iIboBpUpPXHIxkfjTB47t
iCR4f8S8DJzo8w/9l5rrqKAPOvEXiL/hILK206y0PXlmbULOQvPpcsaKq3EbMSzLgYAJr0WiigAo
oooAKKKKACiiigDkvA/+u8T/APYduP8A0GOrfjDUL3SfCmpapp80cc9jA9wolj3q+1SdpGQefUGq
/hT/AJDvi/5SP+Jsv4/6NBzUnjuC4ufA+sWtpbT3Nzc2kkEUUK7mLMpUfQc8mgDhPDnizxj4h0DS
L611HTZr25RrmWxFkVYQrceUxD78Zxkj5R0PPHPcXnjvwzYXlxZ3eswxXNtnzoirBkwQMkY6cjno
cg9K808GaXqPhDwzBdWnhTVB4mFlNaShbdRFIzSl45GbPO0YB4JI47Cl+I2ja1e+NtM17RPDlxc3
WkmJZmeDKXu1i3yjGMLtxk4J3Db90GgD07U/Gvh3R4rZtS1SK2+0RrLGHDbthIAZlAyq5IGWAGeK
5vTfHl0fiL4i0bUbiyGj6dZpeR3UcbAhWEbAs24ggCTqAM4zxXNa/p2qD4iT69c+FdQ1nQ9d01LW
WzVMS25wp2sM/KQyA5yB8xIORzJp/h3WZ/HviyYaLPZ22oaF9htyRmJZRDGuwOQMqCrANjBAB70A
ek2njLw5dz2MFvrFrJJfAm1VX/12GKnb64KkfhXF/EH4nDQVtf8AhHtS0+5uFvhaXNu8TPjIJYhg
wGVIAIGcbhnHGeI8M+HvEn23wHDP4d1K1j0d7mO5uJYgADJKxBABztAZeSBnnGQM1Rk8M+J4vAtr
4T/4RjU5L+y137U1ykYMMkexhlXJGcn8BgZIJAoA981PxVoOi38dhqWq21vcuoYJI+CFJCgt2UEn
GTgVzvxD8fQ+GtHvjpupWH9r2oRzaTIZMgsBtbaw2kg7hk5IHA71xPibw3qP/CyNZu9R8O6xqmka
1bxoi2EmCGVUwkpBwqhl5JOBwRnBrIvfDfiDSdN8daI/h/UbuXVWgltLi2jaeMKr7tpc8nCkD146
UAe5eHdRl1HwppWq3ZjWa6sobiUrwqs8YY4yeBknvVG28feF7q5MEGrxySCF5lARsSIgJZkOMOAF
b7uehpnh+G8t/htp9pJpzfbYNKSFrS4wu6RY9u1sE4BI/I/hXj3hPw34r0nxl4c1q78MX6Wlp9oV
4Igm2BX8zhF3Fgo8zd8xLE5AzgUAbNj8YNVmn1PXrh7JdAs5pYPsYhfznyp8ghsYLMwIbJAAB4zi
vRLT4gaC3hzTtWvL5LYXqDahRyzOFBcKu3cwXuQMe9eXWHhXxDN8KfGWjnRLyO+vNQW7t4ZUCmSP
zI2IU5xuAVjj8s5q5rfhzxJNfeC9dk0G+uLaxshZ3enwXASeMAFS2VIwWU5wD2CkjNAHpV58QfCu
nm3W61q2i+1Q+fbuQxSROeQwGD0PGc5461s6Tq9jr2mRalptytxZzZ8uUAgNglTwQD1BFeRXvhK7
Gv8AgOKDwvPDpenSTST24JmW3WSXcoZmJ3N/EwBIBJA4Ar2W0s7WwtI7W0t4reCJdqRRIFVR6ADg
UAWqKKKACiiigAooooA5L4lf8iFff9dbb/0fHXW1yXxMOPhtr+Rn/RW/mK62gAooooAKKKKACiii
gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKA
CiiigAoopAAM470ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAhAIIIyDS0UUAFFFRjdk5A6
8YPb/OaAJKKKKACiiigAoopM84wfrQAtc74f/wCRg8Wf9hOL/wBI7euirnfD/wDyMHiz/sJxf+kd
vQB0VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK+FN39veMNwwf7WXH0
+zQYrqq5fwwMa/4u+XH/ABNEPbn/AEWDmjx7r1x4Z8Earq9qiNcW8Q8oPyoZmCgkd8Fs474oAuye
I9Ih8Qx6BLfqmpyruit2VgzrgtkEjBGFbkHsR1FbdeBWsuot8WPAOp6nqEl/Jd6O13l0RCjNDKzK
NqgbcnjOT71e8JeMfHfikwapbkDT7yWe3lLfZljtXx+58oFhIxBPzBgcjp1yAD2aOaOV3CSK5jfY
4VgdrYBwfQ4IOPcVDqep2ej6dLqGoXCW9pEAZJX4CgkAZ/EgfjXgng/xD4g0v4U32uxa5FHJNqzL
PJeMjFQQpd1+VmaQ/wB054BIU1dfxpr2rfD7xx9un846RdpFD9rs4izxtIVKSptKkgAHgAhu+KAP
XrbxboV3q0GlW+pRSXlxAtxDEAcyRldwZTjBBHOc1v14C2rva/EjwlrMsSs8Xg8XbRxIFBIimYqq
jAUcYAHAq5oHxC8aSaIPE9xAl1pL2t28+4QRxxTRh2jEQV/MYfKqsGGcZIyBmgD1i78T6NYazbaR
dXyRX9yQIIWVgZCfQ4wfzrar53l1DV9W8S/DDWtV1Nbx76aSVUWJY1iO9QVXaMkY2jnJyD616L8X
tb1Xw34IOqaPqElpcR3Ea7lRGDK2QQQyn68YoA9DorxLxH4g8c+E7bTf7R8QRXI1m8hVHgtoonto
9oMiqX+TJLABmJAC5JGTiTUvFPjXTNJ02y1G9ht719QltpFgMM19OmFaIKihkDEN82QBgqcjdQB7
TXNR+NvD0y6kyakoOmRmS8V4nVoQP7wZQc8HjrXlNj8S/El74F8Ps96kWpajrX9ny3wgUmOMFSTt
27d3zDtjAPGeRVs21Ky134q+XetJdW9p5hllijJlVMn5kK7GBXIPy85OMZoA910zUbXV9Og1CxmE
tpcIJIpApG5T0OCAR9CK0K8B0/xZ4rk/4QOwstXWzTWbZkl2WcJWMq7KGVQoA+Xbx04HHrJafEjx
XcfDOLUXuAbldbGnXWoJApaOHarbtuNoYltudpHTjJFAHvVc7qPjLw/pGpDT9Q1OGC5yoZGDER7v
u72AKpnHG4jNcx8NtT8Q6xd67Nql/cXul2901vp08kCRidATl/lVSeAvI4O48cVwvxG0HVfD6+Mr
yaCG607xE9sLaRJgJEmWQMq7Dyxxu+7ngA+uAD6CByM0tZXh22ubLwzpNreNuuoLOGKdvV1QBj+Y
NatABRRRQByPxKAPw614Fgo+yMckZ5yMD8elddXJfEsZ+HGvDn/j1Y8DPcV1tABRRRQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUmOc5P0qNywA24JyOCccZ5P5VLQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABXO+H/APkYPFn/AGE4v/SO3roq4Syudfh8U+KBpemWN1bm/iLNPetC
wb7Jb8ACNgRjHOe/TigDu6K5g6n4vB48N6Yee2rt0yf+mP0/OnPf+LghI8O6YT/dGrtk/nBigDpa
THOcn6VzB1TxgN//ABTGnHb0/wCJwfm47fuf54pg1bxgdmfC1gNwyc6x0Pof3PX6UAdXRXJyat4x
A+XwnYsc4wusD068w/hR/bXjT/oTrT/wcr/8aoA6yiuTXWfGJ+94Qth9NXU+n/TP61KNS8Vup2eG
7JAo5E2q7ST7bYmGPrj6UAdPRXNnUfFoxjw7pZ5xxq7fn/qKP7R8XZP/ABTml/X+125/8gUAdJRX
LvqXi5enhnTX5H3dXb+sI6VGNW8ZbmH/AAiliADgH+2Pve4/c/zoA6yiuUbV/GIXI8J2JPPA1jn/
ANE0DWPGRUH/AIRCzBPb+2Bx/wCQqAOrorkv7a8Z5I/4Q6z+v9sr/wDGqDrXjQf8ybZn/uMr/wDG
qAOrACgAAADgAU6uSj1nxe2PM8IW6jHbV1JB9Puf1pf7a8XYX/ikrfOOR/aq8H2+TntQB1lFcqmr
+Li37zwlbqOOV1VSff8AgFeOX3in4iRfFnVbfw/aXDyl42m01m+0QIPLQfM3AUHg7gV64zQB7R4b
ZZPEHiwgYxqUan6i1grT1LTbPWtOn0++gWe2uEKSRv0IP8j7jkGub8DS6hLdeJZdUgitr9tQj86G
KUyIrfZYOASBn/IycZro9V1K00fTrjUL6XybW3XfLJsZtoz1woJx+HHWgDm9O+GPhfS9VstTtre6
N3ZLtt3ku5W8sAnCgFvugEjb0x25OZ9J+HfhvQddl1ewsminZ2kWMys0UbsCCyoTgHBIz2BIGBRZ
fErwfqTSC11+2YxwG4csGULGDgklgADkjg88jinH4ieFf7Mk1I6ugtIpFikYwyAozAsu5du5QQMh
iMHsaAM5vhF4NOlz6b/Z0gt5rhbggXD7lZQQApzwMMwx7/TEi/CjwpHbapbR2l0kOplTcIl1IA20
7h39eec81r6L408PeIbq4t9K1aGeWCMSyLhlIQ/xDcBkdORkDI9aTTvGnh3VJngsdTSeURtKqqj5
kRSQWjyv7wAgjK56UAU7X4deHrbULC/WO7e6sIBawPJdO22EAjyyCcFcMRgjoaZo/wANPC+hyXLW
lhIY5g6+RNO0kSBxtbapOASvBPXHGcU1fif4MJQL4gtjuJCqFbdkAMQRjIOD36njqCKp6B8UtC1j
SZ9TuJ/skQuzbwxsrM8gJwnyqpJZsMdq5xj8aAJbL4UeF7G6sZo4r1msHL2iNey7YCWDYUBhgZBP
vk5zXQ+IfDWl+KdPFhq8Ek9qHEmwTNGCR0ztIz16GrNlq9hqWkrqtpcpLYlWYTAEKQpIY8jPBU/l
XKeHvih4e1xdauDfw29pp8rbZJWIMkICDzCCOAWbaB1PHGTQBt6z4N0TxBocGkapaNc2tuFEJeRv
MQgYBD53Zxweee9UJ/hn4SntrC3k0nMdjK8sP7+TcWbbuLNuyxO1fvE8KB04rS0DxXo/icTrpd2Z
ZLfb50ckTROgYZUlWAOCOQcYNcH4u8da/D4u1zR9HntrRNG0htRJliDm4ZSjFTk8Dax6c5H5AHTR
fC7whHpEmlppQ+xvcLcbfPk3CRcgFW3blwCRgEdTRF8MvC0KagEsrhX1GPybtxeTFpVyCQWLZOSB
k9+c9TWj4T8SJ4j8FWGvzqlus0BkmGcKhUkMcntlT+FUH+Jnhg6Zd38F+80VrCLh0W3kVmQnClQV
GQTxnp1OcA0AEfwx8LQtp7pa3avpqlbRlvpgYQSSduG45JrnvFHwuhXw/Zab4WgmtoU1Rb64Ed64
lBCMpaNnYqG5HXHStPw78VdD1XSdMn1C5+xXt/J5SQCCUrvLYCh9u0nBXPPftW7aeNvD97Zajdwa
inkaa229eVWi8lueCGAOcgjHrxQBz3w98Ma/oWqalLe32qvpcsaLb22qXSzzB+rPlGKqO2Acnv0F
dO/hXTJNdTWrtJry7iYtB9plZ0tyf+eafdU++M+9cLpvxCub34mahp8GoedoiaY16u6zZXjYBT02
hyMHPTJBGO1bPhPxzAPBcGq+Itd0+4eS5a3We0jcLI2flVVKhmbHYLQB6BRXLTeO/DUNpZ3jatC0
F4jSW7xqz7lXhmIUEqFPBLYwcg4robeeO6to7mJt0cqB0YDGVIyDz7GgCxRRRQBy3xG2f8K61/eC
R9ikxjPXHHT3xXU1y3xBdU+HviAs20fYZRndjkqQP/1d+ldTQAUUUUAFFFFABRRRQAUUUUAFFFFA
BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRTScDIBPsKAHUUUUAFFFRqCM7iDycYGMD0oAko
oooAKKKKACuc8PZ/4SHxZxx/aUXP/bnb10dczoEn/FReLV2njUoTuxwc2lvx9eP1FAHTUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACZ5xS0mOc0tABVeOGKJpXjjVGlbc5CgFmwBk+pwAPw
qxRQBzPhvH9v+K8Nn/iZR+n/AD6QelL44t7m88E61aWltNc3FxZyQxRRAFmZgVHUjjJ59qZ4a3f2
/wCLN5BP9pR4xnp9lgx1711FAHii/D+8v/gamlQaMlp4gjiCMs0arLJtm8wrvz0PUZOM46dsPxHo
00Hwq1zULzwzPpV61vZRXE9zdtK9xKsqKWAZmCqBgA8H5sdBz9D1h+IfD+neKNJbTdVjlls2YM8a
StHuK9MlSMgHnB4yAewoA8jtPCmr+KNWsr20sZ9NtF8Kix+0TYUTStEyqAAxJUbgcjsv0qTwv4U8
QR614Na40u7sk8O29wL2Zwo3szMQkZUneCCOnGGPfNex6Zp0Ok6bDYWxk8iABI1kkZ2VR0G5iSQO
g9gBWjQB5F8JfCcun6HqiazoH2fUzfPPbzXMKlgrIFXa3OCCGzjGN3vXH6Z4Q1xvh/a+H9W8Papa
Nbai86XtuokkhYq2HWNTllBCg4OTuyvK8/RtITgEntQBx/w3sdZ07wNY2uuptvlaQkYAYqzswLY/
iOcnvzzzmvLLTwN4ovPAPijwsNJlguDqTXsU0zBY7nBQBEPfIVm3HAyFHc7foJTkA4Iz2PanUAea
eDdH1Z/H2seIryxn0+zmsre0hiuCokkZQu5iFJwAVIGeufrSfEbwt/wlEps9O8P+Zq0yrA+ryt5U
dvCTlskMGkOMgKARycnjB9MooA5b+xY/D/w9n0bTrU3gtNOkjigIINw+w8HHOWYnOP71eXeGfAvi
Gx0rxPZWVleDT7zSHgtINSCLKk7E5iDA4Kj5ju+VSWBwDmveqKAPBJvDHikeBfBgPh+Uz6FqIklt
VlUyyRhg24DOBzlcZJ6HvxTbwR4r1Tw544tzot1Z3WpaimoQQyOhWVRI7GPIbG4bgfQ4FfQ9FAHi
mnWPiW4+JMviGbwve2to+jG0cHy8hwgzhQ+cblwAMnGOBnjlLTwP4si8LeGZ10W/afRtSlmmsvM8
p3RmjYNGQwI+6QSMEE5r6WooA+fdf8B3U9panSPDep6PcRRzT2jQTm4YMzYEc5LHBYDOVJC7sNnk
j2vw/Fe2/h3TYNRSNL6O1jWdYgAocKAwAHGAfTj0rXooAKKKKAOV+ISI/wAP/EKumQLGVsc9QpIP
HuB/XiuqrmfiACfh74gw2D/Z83OcfwmumoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiii
gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKA
CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACua8PMD4k8Wrk5GoxHHbm0t/8K6W
ub0BR/wkHi09zqUQP0+yW/8AiaAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiig
AopD0OOTS0AcGmuroHiXxHHPpGszLc3cU8UlnpssyMv2eJCQyqRncrD8Kv8A/CfWg/5gPif/AMEs
/wD8TXW0UAch/wAJ/ZZA/sLxNk9P+JLP/wDE+1B+INkFydE8SAYyCdGn56f7PvXX0UAcg/xBsIwC
+jeJFHQltGnGP/HaaPiBpu2UnS/ECbCB82j3HzZ54wvpzzjiuxooA49fiFpLJuNjrqp2c6Pc7T6d
E70H4haC6FTHq+CMEf2RdcZ6/wDLPtXYUUAckfiLoAJG3VtwBO3+yLrP/ouj/hY/h/8A6i3/AIJ7
r/43XW0UAcl/wsfw/wD9Rb/wT3X/AMbpg8f2TDKaL4kdezJotxhh2I+Xoa7CigDkT4/sx10LxMOM
86LP0/75oHxAsj/zAvE3b/mCz9+n8NddRQByJ+IFmASdC8TADr/xJZ+P/HaafiHYK206J4kBxnB0
afp/3zXYUUAccfiHpwbYdG8RB923b/Y8+c9v4aB8RNNILDSfEO0DO7+x58H/AMd9j+VdjRQByEfx
B0eVgrWmtxscEBtHuckEZB4Q8EUo+ImhFgDHq4ycLnSLr5vp+7+n5111FAHID4h6G7kJDrLADJZd
HusfT/V5qU+PdFGP3WrkkgY/sa77/wDbP2P5V1VFAHnPizxlpGqeEdY0+zh1Sa4ubOWKJP7Jul3M
ykDlowBz3Jr0aiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK
KKACiiigAooooAKKKKACiiigAooooAK5fw//AMjL4t54/tGH5cd/skHOfy/L3rqK5nQOPEfisZBB
1CE8HOP9EgHPoeP5UAdNRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVX
e7t4nKPPEpHVWcAj8Kb9utP+fuD/AL+D/GgC1RVX7daf8/cH/fwf40fbrT/n7g/7+D/GgC1RVX7d
af8AP3B/38H+NH260/5+4P8Av4P8aALVFVvt9pk/6TDx1/eLx+tILq2cbhPEwHUhwcdv60AWqKjE
iMgcMCpGQc8Gn5GM5GPWgBaKKqm+tVJVrmFSDgguAQfzoAtUVV+3Wn/P3B/38H+NH260/wCfuD/v
4P8AGgC1RVX7daf8/cH/AH8H+NH260/5+4P+/g/xoAtUVV+3Wn/P3B/38H+NH260/wCfuD/v4P8A
GgC1RVX+0LTr9qg/7+L/AI0v2y25/wBJi4OD846+nWgCzRVdrq3VdxnjC5xkuMU8SoV3B1KjqwIw
KAJaKhEiFzGrqWHVQwyPwqagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooo
oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiig
AooooAKKKKACiiigAooooAKKKKACiiigAooooAK5TQJMeLPFkLY3C7t5Bzzg20QHHXGVb9feurrm
dHZz4x8S55UG1VTnt5ROPzP60AdNRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAB
RRRQBwlp4Z0HWPFviiTVNIsb25W6h2Pc26yERm2iAwWB43K34g1rHwB4PJJPhbRsnn/jyj/+Jo0f
H/CY+Jfl5za846/uz/n8a0tZOonSpl0hITfMoWFpmIRCSBubAOQAScd8Y70AZv8Awr7wd/0K2jf+
AUf+FH/CvvB3/QraN/4BR/4Vxng7VPGFn8TNQ8L67qyavbxWYuzcpAsZjJK4GABjOWGDnsRjmu71
3xNpnh2S0hvZJDcXTMLe3giaWWXAy2FUE4A5JoAr/wDCvvB3/QraN/4BR/4Un/CvPBvH/FL6Rwc/
8eaf4VSvPiX4SsdHsdWm1TFhfFlgmWCRgSv3lO1SVYZ6HB60+1+Ivha90i/1aLVP9D09lS6Z4XQx
sxwo2soYkngYHXNAFg/DzwccD/hF9I49LRB+fHNC/DzwcoIHhnSsHGf9FXt+FVbL4keGdQvpbSO9
mjmigNxMJ7WWIRRbQ+5mZQFG0ggk85GOtPh8f6BqdtdCwv5RPFZm8USWkqsYcHEqqygyLkfw5oAl
/wCFeeDtqL/wjWmYTG0fZ17evr+NN/4Vz4OLEnw5p/zdcR8du3bp/P1NYGg/EfSrDwlo914k19bm
4vWlCXsVlKkUpWQjAAQY2jAOQOmfettfiP4Wl8O3evR6oGsbSTyZiYmVw5xhdhAbJzxx6+hoAkPw
58Hsm0+HNPxnPEeD279e3SpF+H/g9UC/8IvpBwOrWaMfxJGTTNB8daP4g1SfSrJb1b2Bd00M9o6e
WpAILEjAzngE5NLqnjjQ9H1iTT7h53uIvK87yYGdYfNbCbiOF3Ej8xnqKAJf+FfeDck/8Ito/wD4
Bx/4Uh+Hng05/wCKW0jn/pzT/CsS0+JVldeLNb01rS9Sz0qEGSb7HKx3jczlgqkqoUDbuA3EHHat
Ky+Inhm+l0uO2v5GOqlhZM1rKqzFWKsMlcAgjnOO3qKALX/CvvB3/QraN/4BR/4UH4feDiR/xS2j
8f8ATlH/AIVwnxM+Jf2HSLg+GNVuEvbK8W2mkjtFkt2YglkLspG5QueCO/XHHQ2XiV3+Id9Z3HiC
IWdrpSzzWElq0ZhYbWaUylQpXDDo38XT5c0AbB+Hng0/8yxpPf8A5dE7/hR/wrzwbu3f8IvpGcY/
480x+WKpW3xK8K3NrdXQ1Fo47aD7QzTQPHvi3bRIgZcspbgEZ54rW0HxFp3iNbk2TTFrZlSVJoWj
KsRuAwwGcgg5HBBFAFT/AIV54O4P/CL6Txj/AJdE/XjmkPw78HEn/imdK56/6MvqT6e5/T0FdVRQ
BzH/AAr/AMHHAPhjSOO32NMfy96gX4eeECpQ+GLBFUbQfIX5h1zxyfTnmuuooA868X+AvC1r4Q1q
7tPD9jFdw2MzxSRQhWRghIII7jGa9ASRJY1kjYMrAMpHQg9DWV4u/wCRM13/ALB1x/6Lar2nKqaZ
aqoAUQoAAMADAoAuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAzJ3Y2nGM5/pT
6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAiRWGdz7skkcYw
PSpaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub0dw3i7xImCCr23O3AO
YvXuf/rV0lcLHo8WreN/EAkutStnjW1P+i3ksKsCjckKQCeCM+woA7qiuWPguAnP9u+IhyDj+1Jf
y60sfgyBM7tb8QPnGN2qzcfkRQB1FHtXJ/8ACEoVx/wkPiLGP+gk3qDnOM9qD4KVm58SeI84I/5C
B6H/AID7UAdZRXNr4UcJtHiHXse92CfzK5pF8KsmdviHXeTnm6U989196AOlornf+EVkyD/wkeu/
T7Sv/wATVc+D1kGZvEPiCQ8YP28pgemECg5980AdVRXJt4IiKqB4g8RgqMFhqkmW9z/9bFH/AAgs
YOf+Em8T/wDgzb/CgDrKK5dPCBjcMviPxASBj5r0EfkVp/8AwijhNo8Ra+Pf7UpP5laAOlornD4U
dhg+I9e/C6Uf+y0weFJBkf8ACS6+SR943K//ABGKAOmormz4VkYY/wCEk10cg5Fyn/xFN/4RKX5f
+Kn8QfLj/l5Tn6/JQB01FcwPCkoTafE3iAnGNxuEz9fuYph8HXJkLDxd4kCn+ATw4H/kLP60AdVX
PR+LdEPiO48PNfxxapDt/wBHlO1nDKGBXPDcHoORjpVY+D5yRjxZ4iGDni4i59v9X/nFeaeIPgrq
viLx7Pey6tLHpmyIG7uXEtxMwUA7VUKBjGMnGOoBoA9Q0eMDxl4lkAGWNqCcc8RH/GtHV7m+tNKu
Z9NtBe3iofIgaRUDv2yzEADufYcVzfgvSDoWta5pqXV3dxwi1CzXcxkkY+Wc5Y9umAAAK7igDyjw
DYeOrHxJK+uaNZ20V3I9xqF+J1kluGwwjjADHaq5GABwF68nOj4w0DVP+FgeGvFdhZS6hFYJNBcW
kTqHAZWCuoZlU8tzyDwv4ejUUAfPp+G/iWw8I+GrEaU15cQas+pXcKzRbYk+UCMlmAZiF7DGSfxj
13w9qeleGfiFd6zoEqw6rfR3Vk3nREhmnYKCEYncPMBxgg8jPNfQ1Z2o6ZaazZS2V9Ak9rJgNHIu
4HByD9QQCD1BFAHg+k2lvr7a5o0lnrtp4m1vTlhhn1G0FvCywquFCgnGQigsc+2M4PRaR4W8Rtq9
hqk+kPZf2R4d/s1YQ8Ra4uNrLhMMV2/MDuYjnj1x6XpvhvSdLuvtFpZhbjy/KE8kjSSBM52hmJIG
QOAew9K3KAPnuy8FeK4PD/gizk8O3DS6Jqcl1dATwkGMyq4C5kwSQDxjt781tW8Papp3g7xrJrGi
XEZ1XVoprLdJHuJaVsYCscthumMHPU9vo2s/UdLsdWs2s9RtIbq3fBaKZAwJHQ4PcetAHmPwzvIj
4x1MalpWu2uvX1qsz3GqIqiSKIqgChVUDGVzwenUdKr+NvA2u6343/tXTNNltbyKSAQajFPGIpYw
AX85S24FTkAqpDAYK9DXp2meHdK0Z2lsLGKKZ1CvNy0jAdAWYliPbNbFAHk9n4S8RWnjrxqwsoDp
uuQHy71pgAp2MAu0ZbO5hnOBgE88CuY8O+C/GdneeB0u/DrRW+h3UxmlW8iYsJJNxbbu4AB9STg8
DjPv9FAHz5qXgHxlD4R1rwrb6L9sW51j7dDfi6jCuhAHKs24N8oJz6nr32tR8HeJdU8ca3OdLa3s
9U0I6clyZ42VJdin5gG3bdyFchc8g4617TRQB4TpXgjXh4Uay1DwZC97b2v2NppdQ3NdQmVSViAf
bGQpZgTxuVTjkiuv+FnhnV/DFpqdtftOLFp1awiudhmVAuG3FGYY+6ANxHy5AGcV6PRQAUUUUAFF
FFAGL4u/5EzXf+wdcf8Aotq0LD/kH2v/AFxX+QrP8Xf8iZrv/YOuP/RbVoWH/IPtf+uK/wAhQBao
oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKK
ACiiigAooooAK5jR8jxr4mDABSLQjjk/u2B/Dj+ddPXM6KWPjXxQS2QPsqgen7sn+tAHTUUUUAFF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcGfEdj4f8AGeuLqQvEWdbd4Whsp5lc
BMNyiMBg4796v/8ACxvDYyTJqYA5JOkXf/xqutooA5L/AIWP4b3FfM1LIOP+QTddf+/dK3xD8Ogl
fN1DcBnA0q6Jx9PLrrKKAOVTx/4dklCJdXLE9CLGfB4zjOzrjn6Un/Cf+HGZcXlwckgYsp+o6/we
x/AGurooA5h/HvhyNVZ72ZVY7VLWcwBPoPkqIfEXwuQxGpPtXhm+yTYB9M7a6yigDlH+InhaP/Wa
k69etpMP/ZKb/wALK8Jf9Bf/AMlpv/ia62igDkT8S/CI66v/AOS03/xNNPxF8PKMiXUSD0ZdLuip
9CCI8EH1FdhRQByX/CxvDmAd+p/+Ci7/APjVIPiN4bYkCXUiV6j+yLrI/wDIVddRQByafEXw3KFK
T35DEhf+JXdc4OD/AMs6b/wsLw7vaP7TebgwBzp1zgE9s+X/APqyK66igDlE+IXhqR1SO8nYt0As
p/m4J4+Tk8U0/ETwwjhTfThmYKB9in5yMjHydOetdbRQByn/AAsLwwrsh1CQMp2sv2SbKn0I2cU3
/hZPhLGf7WOOmfs03/xNdbRQByR+I3hVSc6owx1zazf/ABPuKP8AhZXhL/oL/wDktN/8TXW0UAee
+I/H/hi88L6va22pmSeaymijQW0uWZkIA+73JFdvYZGnW2VIIhXKnqDgcVbooAKKKKACiiigAooo
oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimnOOACfenUAFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFV/tlt/z9Q/99j/ABpB
eWx6XUP/AH2P8aALNFQ+fESAJUJJwBuHJ9KPOiJUCRCW+6Nw5+lAE1FFFABRRUEk8UQHmSKmehY4
B/OgCeiq3221/wCfmH/v4P8AGj7ba/8APzD/AN/B/jQBKzKilmYBQMkk4AFcvojQDxv4odZI9zfZ
F4YZOIjj+ZrcunsL20mtbiW3kt5kMciM4wysMEHnuCa8A8A/DZNO+Ld8t7JG+naK4mgkZhiZm5h+
pA+Y46MuKAPo+iq32y2GM3UPP+2P8aUXMJGRKhBGchh0zjNAFiikLADJIApNy8cjnpz1oAdRSAg9
KWgAooqGWaGLAklRCeQGYDP50ATUVALy2Y4FxET6BxQJ4WJCyxkjqAw47UAT0U3cOMEc8CnUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFABRRRQAUUUUAFFFFABRRRQAxhkY559Din0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU
UAeZeAfBPhbUfAml3V7oGm3FxNGzSTSW6szHceSSM9q6f/hXng3/AKFbR/8AwDT/AAqD4Z/8k60X
/ri3/obVj/F7VNV8P+Cm1bSdSuLK5gmRMRhWVwxAOQynp2xigDcPw78HOQT4a0wEZIK26jr9Ka3w
88IORnw1pgIOQVt1BHIPGPp/nNZEXxA07w1pWg22vXOoz3upWkcySi2MhlZgCQNijJBYDAGeRWjb
fEXw1deGJPEUV84svP8As5DRsJDLxiML1LEEEAdjn1oAn/4V34Pzn/hHbDrn/V/5/Kmv8NvBrHJ8
PWnTHyqR/I1xPj74iSyeGrTVvCuqXVrLHqo067he3UMrFSxV1dSQRtGCOPmYHnp1V/8AE/w7p1zq
kF217G+lsouw1s37sMwVW91JIwR6j1oAuH4Z+DCAP+EftOP97/Gli+G/g2Ikjw3p757SwiQD6bs4
qhrPj3SEsrW3tX1Ga91GwN7bpYw7pkh2lhIQ3A6Hg5JxjBrnPh/8Q5I/h1HrHiW/kvLue/NpAkca
mWZzt2oqrgE8k8468mgDt/8AhXng3/oVtH/8A0/wo/4V54N/6FbR/wDwDT/Cs9viP4ebSbW+iluJ
Zbu7NlFZxxg3BnGAybScAjIyc4+Yc8isT4UeJdV1+/8AE8WpXl1cpZXgitluEVWjTLgA7VHzfKM5
9qAOr/4V54N/6FbR/wDwDT/Cg/DzwaSP+KW0jj/pzT/CuW+LnjS+8OaBPBoh26htQ3FwCD9ljZtq
nn+JiCB7Kx7Cu/trpItGhu7qUKq26ySyMcAALkkn8zQBkn4eeDiMHwvpHTH/AB5p/hSH4e+Dz/zL
OkjAxxaIO+fSsKX4naHqFjqMOn3F9BcJYy3cE5s2O6JSV85FP3lVsnBxkKeMViQ/FI6fZ+ErIC+1
ifUvmnu1sWUyopKny0GNzbgOmcAZ7gUAdy3gHwk7Anw5pnAI4tlA59sUw/DnwcxyfDthn2jxVKf4
oeGLe/8AsslzOoW5W0kmNu4jimYEiNmxw3B9uDzwcZdz8TlTx3qPh5LC/ENjZu8s0dk8jiUFSG2j
/lmFP3jwxIwcEEgHQP8AD3wfKig+H9PwOQViAzx3I603/hWXgz/oX7T/AMe/xrn/AAj47tofA+n3
2s6zLqd3d3j20DRWjLJcPu4VUAGcAjnAHb66d98UPDdhoMGutNcSWE1wbQukJ3RTAbijqcMpwD2P
T6ZALv8AwrLwZ/0L9p/49/jTo/hx4OjBA8Oac+e8sAkI+hbOKoWfxR8N3en6zetJd26aOFNylxbs
j4Y4UqDydx4AODyMgVseHPFFp4ngmltIbmIQMokE6AcsoYYIJBG0g5BI5GCaAIh8PfBqkkeF9JBP
/Ton+FR/8K88H7if+Ea0wEnJxbqPX/H+XoK6qigDzq/8MaHoPjrwfLpWmW9nJLd3KuYU27l+yynB
/GvRa5LxN/yOngr/AK/bn/0klrraACiimEAkZAOOR7UAPooooAKKKKACiiigAooooAKKKKACiiig
AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKQDA6k0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJfDP/knWi/9cW/9Das34qeH9X8T+EZNG0q0
E80rLIXaZUVdrA7eTkk9u3ByRxWl8M/+SdaL/wBcW/8AQ2rpbm4htLeS4uJUiijBZndsKo9SaAPJ
NQ8N+J7vV/A96mhTFdBhC3Ki6h3MwCrhctg/czzjhh3zWBB8MvFz/D64sBZpbarb63/alvG88bLM
CirgMCQCCM/NgGvoKq000drC80zrHHGpZ3dgFVQMkknoBQB4/wCM/DPizxR4WtLeDwpY2V22pLe3
EVrcRDLKjKzOx2hmYtxjOAvJORVDxl4C8Wal4g8Vz6dpEc1rrdvbKkj3SI0ZQxMQVJ5bMZHXHOcm
vTtC8f8AhXxPqEljo+rx3N0ilzGI3QkA4JG5QG69s11VAHi48DeJ7TVtA1yx0+CaeLRF0y8sri6C
GNljKbgy7lK8g4X06AnIxx8J/FC+AdLsfL059R0zU2u0t3mLJMjBchjgAHKjjPIJ5B4r3We5ghnt
4pZUSSdykSswBdgpYgDudqsfoDVugDxbUfh/rwbw/runaJpdpe6bftdyaTay7VZWEeQZG+UvmM5O
AMMMZ25PRfDjwvr2gav4mvtYtraJdWuzcosNx5hU7mO37o4+brnt0Fdpq2qWuiabPqV68iWsA3yu
kbOVXPJIUE4HUnHAFZEXj/w7cW+jTx3rmPWpWisWMLjzGVtpB4+X5uOcUAcb8Q/hVda5aajd6Nqu
ovfXtwk0ljPdBbViMLnbt6gAYyTjFdvL4babwBL4ca7leSXT2tDcTt5jbihXcx74JrpaKAPHNA8M
+LbPwVeaJe+HtNa5ttPubK2vlnRp5lk3bUU8bFBbJJbkKPlyc1Ri8EeLraLwLdW2lwG70RZYZ4Jr
lQoy2VfcuQV55A+bjp3HuNFAHz74j+HvjbWNW1W6Gl2ZU6mlzbiG7WGN4wGBPlgYLEFSzsd3GBkE
11c3hnxNa/E7XPEEWnW1xZ6npYgJW4XMbiJAVAYDcSyYBOFw2SRgivV6KAPBNA+HvinTdM8L3c+m
q13oWoyyNaGeMiWGQqSyNu2hlKnhiO3pSX/wr8TXPgiewiggF5ea22pvE8ygRRhGVVZhkFjuzxkD
HWvfKKAPFW8C+JJNY8X38mi2U0OtLEsdtLdjBUSoXDEfdJUMQwyVYDFdN8L/AAjqfhG11OC6eZLC
aZWs7WeRZJIVAOdzL8vJPQccZ4JIr0SigAooooA5XxIH/wCEr8H4chP7QnyueCfsk+Dj25/Ouqrl
PEjAeL/BiYGTf3Bz34tJv8a6ugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKK
ACiiigAooooAKKKKACiiigDkfhtx8PtJQ/eiWSJvZllZT+oNcl8dGu4vDWlC3vpreGfU44JoUI2y
AgspPGTtKAgZxzyDgY6/4bf8iPa/9fN3/wClMtaev+G9J8U6d9g1qzF1bBxIqFmUqwBAIKkEHBPf
vQB5brviXxGniXxFpFtr9zFF4e0Vr2OdY4t11MFVsyfLgjDFcKAOM9a9C8NXyeMPh/p95qtsjLf2
gNzEy4V+zcf3SQTj0NNv/h/4Y1LyxPpgURwC1xDM8QaEEERtsYblyAcNmti50izuNHfSDF5di0Pk
GKBjFhMY2gqQVGOOO1AHmOh/2DrXxek8RWVzZW1nbwf2bZpE6hr2fDbnVV5Kqu5d3faCDgVp/Fbx
JrvhldJuNNmuEsSZmvntkjeVFAUI2HVhtDNzwASVXcu4Vs6H8LvCHhzV4dU0rS2hvYQwSRriR8bl
KnhmI6Ejp3rV1zwrpfiJ4ZNRjnLwxyRKYbmSIlJMB1OxhuVgoyDmgDyGS6u9Z+KHgV7jxBdsLrRh
cPcQMsarJ5UgdkDKAoYpzlc8nGOAMzVPGHiWz0LxbJF4jvxJpOsrZ2rOV3GMmVSrZUZOFB6ZGK9p
uPA3hm6l02WbSLeR9MRY7Qtu/dKpyq4z8wBGcHPf1qpffDPwfql/PfXmhwSXFy5kmfc672PJOFYD
JOSSBzk+poA8+8U65qviHW/F+jPqU9nYaVoBmWGLaBO7RozGTIOQQ5XAxgYIwaydJ1LUNL0L4UJa
XjRxXl40c0LopyPtAGV3AlSVdlyCMgivXdU+HnhfWbqK61DSlmmigFvvM0gLRgYCsQw3Y9WyeBzQ
vw88LhdPQaUFXTnL2QW4lXyWLBiVw3B3AHPXgelAHm3hnxn4u8QaxPrMd2sdlbar5F3aXE8UUMNq
2Aq4b5vMyTg55Ix7Va+GvivxDf8AjY6V4j1C6EzWks/kOEaGbcyMjxMi/d27v4mUjkHkgegL8PvC
qa/Jra6NAL6VyzvltpY5y2zO3dyecZyc9am0XwXoXh+6judPtpVligNvF5tzJKIoydxVAzEKCRnj
FAHTUUUUAFFFFABRRRQAUUUUAFFFFAHJ+KMp4l8H3B/1a6lLG3rua1mC8fWusrlPF4zqfhI5Axra
nB7/AOjzjj866ugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikzzjB+tAC0UUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRSE
Z7kfSloAKKKKACiiigAooooA4LStE8aaFYLp+nX+gNapNLIhuLaZnAeRnwSrgEgtjoKvtF8Q9p23
vhgn0NncD/2rXXUUAcj5fxABG668NMvGcW04PUZ/jPbI/X2pwXx4C+6Xw6wyNuI51475+Y/5/TrK
KAOVb/hPNp2f8I3uz/F5+MVGW+ImeIvC+PeS4/8Aia66igDkt/xB/wCeHhj/AL+3H/xNJj4gyfx+
GYMd9txLn8Mrj9a66igDkvJ+IP8Az/eGP/AO4/8AjtHk/EH/AJ/vDH/gHcf/AB2utooA5IxfEHAx
feGPf/Q5/wD47TlTx0Dk3Ph1hjoLeYc59d57V1dFAHKlPHOzAufDu7B+Y282M5GON/pnv6U8jxxv
IB8PbezETZ/L/wCvXT0UAcvnxxvwB4fK56nzgcfSo2bx58u1PDhOPmy045z2454rrKKAOU3ePsn9
34ax/wBdJ/8A4mmM/wAQgeIPDBHqZZx/7LXXUUAcgX+IW0EW/hgnI486f/4mmgfEOTln8NQY6Lsn
l3e+dy4+mDXY0UAcmF8eLJzJ4ddc/wBydSBgf7RzzmgHx7zkeHMY4wZ+uP8AHj8M98DrKKAOIm0r
xdquqaRNqraLHa6fei7ItHlLviORMfMuP48/hXb0UUAFFFFABRRRQAUUUUAFFFFABSEZx1paKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAaRk
EAke47U6iigAooooAKKKKACkAwOTmlooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigA
ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopinIzz
z6jFAD6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK
KKACiiigAooooAKKKKACiiigAoopMc5yfpQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAUU3AznAyOM06gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopCcDoT
S0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFA
BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUnfGPxoAWiiigAooooAKKKKACiiigD//2Q==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-11-05 10:51:16 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASwAAAGnCAIAAACCaP05AAAP50lEQVR42u3dv24dxRfA8SvRULhI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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-11-05 10:51:16 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAnQAAAEACAMAAAAN7Bu3AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2009-10-22 12:03:44 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Kaplan-Meier analysis of time to pulmonary embolism</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-05" MODIFIED="2009-10-22 12:03:41 +0100" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Kaplan-Meier analysis of time to deep vein thrombosis</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-11-03 15:53:52 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-11-03 15:53:52 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-10-22 12:36:09 +0100" MODIFIED_BY="[Empty name]">Search strategy for CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-03 15:53:52 +0000" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor Vena Cava Filters explode all trees<BR/>#2 ven* near cav* <BR/>#3 Tempofilter<BR/>#4 VenaTech<BR/>#5 Bard near G2<BR/>#6 "Bard Recovery"<BR/>#7 "Boston Greenfield"<BR/>#8 "Birds Nest"<BR/>#9 Cook near Celect<BR/>#10 "Gunther Tulip"<BR/>#11 OptEase<BR/>#12 TrapEase<BR/>#13 Mobin-Uddin<BR/>#14 (ALN)<BR/>#15 (Rex Medical Option)<BR/>#16 Simon near Nitinol<BR/>#17 IVC near filter<BR/>#18 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>